Mammakarzinom

  • Ossi R. Köchli
  • Bernd-Uwe Sevin
  • Jörg Benz
  • Edgar Petru
  • Urs Haller

Zusammenfassung

Rund 8% aller Frauen, welche das 75. Altersjahr erreichen, erkranken im Laufe ihres Lebens an einem Mammakarzinom, d.h. etwa jede 13. Frau (Cutler et al. 1976; Frentzel-Beyme et al. 1979; Leis 1982). Verglichen mit der Erkrankungshäufigkeit an Karzinomen der Cervix uteri, des Corpus uteri und des Ovars ist das Mammakarzinom führend (Benz 1989). Weltweit weist die Inzidenz große Unterschiede auf. Mit wenigen Ausnahmen ist jedoch eine deutliche Inzidenzzunahme zu beobachten (Arellano et al. 1972; De Waard 1978). In Zentral- und Westeuropa stieg die Brustkrebsinzidenz von 1956 bis 1975 um 20% (Becker et al. 1984, Statistisches Quellenwerk der Schweiz). Eine analoge Entwicklung wird in den Vereinigten Staaten von Amerika beobachtet (Blot et al. 1977; Frentzel-Beyme et al. 1979). Nach Hochrechnungen von Krebszentren im Saarland, in Baden-Württemberg und in Hamburg wird die Zahl von Neuerkrankungen in Westdeutschland momentan auf 25 000 Frauen pro Jahr geschätzt (Bahnsen 1987). Das Züricher Krebsregister gibt für die Schweiz 1986 ca. 3600 Neuerkrankungen an.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aigner KR et al. (1982) Die isolierte Leberperfusion mit 5-Fluorouracil (5-FU) beim Menschen. Chirurg 53: 571–579PubMedGoogle Scholar
  2. Aigner KR et al. (1985) Die isolierte Leberperfusion. Onkologie 21: 43–83Google Scholar
  3. Alanko A, Heinonen E, Scheinin T, Tolppanen EMN, Vihko R (1985) Signifance of estrogen and progesteron receptors, disease free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56: 1696PubMedGoogle Scholar
  4. Alt D, von Boehm G, Weiss G (1986) Miteinander reden. Brustkrebskranke Frauen sprechen mit Experten. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  5. Amalric R, Santamaria F, Robert F, Seigle J et al. (1981) Curative radiotherapy for operable breast cancer: 5- and 10-year results. In: Lewison EF, Montague ACW (eds) Diagnosis and treatment of breast cancer. Williams & Wilkins, Baltimore, p 185Google Scholar
  6. Amalric R et al. (1982) Radiation therapy with or without primary limited surgery for operable breast cancer: a 20-year experience at the Marseilles Cancer Institute. Cancer 49: 30–34PubMedGoogle Scholar
  7. Andersen J, Nielsen M, Jensen J (1985) Essential histological findings in the female breast at autopsy. Early Breast Cancer, Springer, Berlin Heidelberg New York, pp 52–64Google Scholar
  8. Anderson DE (1982) Die familiäre und genetische Prädisposition bei Erkrankungen der Burst. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stuttgart, S 1Google Scholar
  9. Anderson JA (1974) Lobular carcinoma in situ: A long-term follow-up in 52 cases. Acta Pathol Microbiol Scand 82: 519–533Google Scholar
  10. Andersson M, Mouridsen HT (1987) IV. Mitoxantrone as single chemotherapeutic agent for advanced breast cancer: The phase II trial experience. In: Mouridsen HT, Zalmen AA (eds) The role of mitoxantrone in malignant diseases. PharmaLibri, Chicago, pp 31–47Google Scholar
  11. Anton HW, Guhr A, Müller A, Abel U (1989) Multicentricity in breast carcinoma. In: Kubli F, von Fournier D, Bauer M, Jungermann H, Kaufmann M (eds) Breast diseases. Breast- conserving therapy, non-invasive lesions, mastopathy. Springer, Berlin Heidelberg New York Tokyo, pp 48–56Google Scholar
  12. Arellano MG, Kinden G, Dunn JE (1971) Cancer pattern in Alameda County, California. Br J Cancer 26: 473–482Google Scholar
  13. Asbury RF, Bakemeier RF, Fölsch E, McCune CS, Savlov E, Bennett JM (1981) Treatment of metastatic breast cancer with aminoglutethimide. Cancer 47: 1954–1958PubMedGoogle Scholar
  14. Ashikari R, Hadju SI, Robbins GF (1971) Intraductal carcinoma of the breast 1960–1969. Cancer 28: 1182–1187PubMedGoogle Scholar
  15. Attiyeh FF, Jensen M, Huvos AG, Fracchia A (1977) Axillary micrometastasis and macro-metastasis in carcinoma of the breast. Surg Gynecol Obstet 144: 839–842PubMedGoogle Scholar
  16. Auchincloss H (1963) Significance of location and number axillary metastases in carcinoma of the breast. Ann Surg 158:37 Auer G, Caspersson TO, Wallgren AS (1980) DNA content and survival in breast cancer. Anal Quant Cytol 2: 161–165Google Scholar
  17. Auer G, Askenstein U, Ahrens O (1989) Cytophotometry. Pathologe 20: 518–527Google Scholar
  18. Bahnsen J (1987) Bedeutung der Mammographie für die Brustkrebs-Vorsorgeuntersuchung. Gynäkologe 20: 243–253PubMedGoogle Scholar
  19. Baker LH (1982) Breast cancer demonstration project: 5 year summary report. CA 32: 194Google Scholar
  20. Baltzer J, Zander J (1986) Histologische Prognosefaktoren in ihrer Bedeutung für eine mögliche individualisierte Behandlung des Mammakarzinoms. In: Herrnanek P (Hrsg) Bedeutung des TNM-Systems für die klinische Onkologie. Zuckschwerdt, München, S 36–45Google Scholar
  21. Bässler R (1978) Pathologie der Brustdrüse. In: Doerr W, Seifert G, Uehlinger E (Hrsg) Spezielle pathologische Anatomie, Bd 11. Springer, Berlin Heidelberg New York, pp 527– 531Google Scholar
  22. Bässler R (1983) Anatomische Grundlagen des Mammakarzinoms. In: Feiereis H, Grewe HE, Johannigmann J et al. (Hrsg) Brustkrebs der Frau. Marseille, München, S 32Google Scholar
  23. Bässler R, Prechtel K, Schauer A, Maass H, Stegner HE (1985) 1. Rundtischgespräch über Voraussetzungen und Konsequenzen der histopathologischen Diagnostik des Mammakarzinoms, insbesondere nach brusterhaltenden OpeTationsmethoden. Verh Dtsch Ges Pathol 69: 237–248Google Scholar
  24. Bastert G (1985) Multizentrische, kooperative Studie zur adjuvanten Therapie bei operierten Mammakarzinomen mit perioperativer Chemo-/Hormontherapie. In: DFVLR (Hrsg) Projekt Status-Bericht 1985. Deutsche Forschungs- und Versuchsanst f Luft- und Raumfahrt e.V., Köln, S 454Google Scholar
  25. Bastert G (1989a) Die Behandlung des metastasierenden Mammakarzinoms mit AntiÖstrogenen. In: Becher R, Höffken K (Hrsg) Die Systemtherapie des Mammakarzinoms. Zuckschwerdt, München, S 65–72Google Scholar
  26. Bastert G (1989b) Malignome der Mamma. In: Schmidt-Matthiesen H (Hrsg) Spezielle gynäkologische Onkologie II. Urban & Schwarzenberg, München, S 131–227Google Scholar
  27. Bastert G, Blin R (1986) sis-Onkogen und Mammacarcinom. (Unveröffentlichte Ergebnisse) Bastert G, Schmidt-Matthiesen H (1987) Neue Methoden zur Charakterisierung von Tumorzellen und Tumoren sowie deren klinische Relevanz. Arch Gynecol 242: 227–231Google Scholar
  28. Bastert G, Fortmeyer HP, Schmidt-Matthiesen H (1980) Thymus aplastic nude mice and rats in clinical oncology. Fischer, StuttgartGoogle Scholar
  29. Bastert G, Eichler A, Kaul S (1987) Monoclonal antibodies against human breast cancer. In: Tygaard J, Brünner N, Graem N, Spang-Thomsen M (eds) Immune deficient animals in biomedical research. Karger, Basel, pp 242Google Scholar
  30. Baum M (1985) Nolvadex adjuvant trial organisation - controlled trial of tamoxifen as single agent in management of early breast cancer: analysis at 6 years. Lancet 1: 836–839Google Scholar
  31. Becher R, Höffken K (1989) LH-RH-Agonisten in der Therapie des Mammakarzinoms. In: Becher R, Höffken K (Hrsg) Die Systemtherapie des Mammakarzinoms. Zuckschwerdt, München, S 73–S0Google Scholar
  32. Beck T, Schweikhart G (1985) Die Häufigkeit des Mamillenbefalls beim invasiven Mammakarzinom und Kriterien zum Erhalt der Mamillenhaut. Tumor Diagn Ther 6: 139Google Scholar
  33. Becker H (1984) Breast reconstruction using an inflatable breast implant with detachable reservoir. Plast Reconstr Surg 73: 678–683PubMedGoogle Scholar
  34. Becker N, Frentzel-Beyme R, Wagner G (1984) Atlas of cancer mortality in the Federal Republic of Germany. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  35. Bedwani R, Vana J, Rosner D, Schmitz RL, Murphy GP (1981) Management and survical of female patients with “minimal breast cancer”: as observed in the long-term and short- term surveys of the American College of Surgeans. Cancer 47: 2769–2778PubMedGoogle Scholar
  36. Beller FK (1982) Angleichung der Brüste bei Krebserkrankung und nach Mastektomie. 2. Tagung Dtsch Ges Senologie, KölnGoogle Scholar
  37. Beller FK (1985) Atlas der Mammachirurgie. Schattauer, Stuttgart, S 17, 21Google Scholar
  38. Beller FK (1990) Die subkutane Mastektomie als Krebsoperation - was steht dagegen? 1. Jahrestagung der AWO, Internationales Symposium über neue Entwicklungen zur Erhaltung und Wiederherstellung der Brust beim Mamma-Carcinom Berlin 23.–25. 2. 90Google Scholar
  39. Beller FK, Schnepper E (1981) Konservative Primäroperation des Mamma-Karzinoms. Dtsch Med Wschr 106: 329PubMedGoogle Scholar
  40. Bennett SE, Larence RS, Fleischmann KH, Gifford CS, Slack WV (1983) Profile of women practicing breast self-examination. JAMA 249: 488–491Google Scholar
  41. Benz J (1987) Mammadiagnostik. Die Wertigkeit von senologischen Untersuchungsmethoden. Der informierte Arzt 8: 56–64Google Scholar
  42. Benz J (1989) Problematik und klinische Diagnostik. In: Mammakarzinom, Mamma-Symposium Winterthur 1988. Bäbler, Bern, S 9–20Google Scholar
  43. Benz-Baumann B, Benz J, Egloff B, Sulser H (1988) Histologische und zytologische Abklärung von Mammaveränderungen. Helv Chir Acta 55: 937–941Google Scholar
  44. Beretta G, Tabiadon D, Tedeschi L, Luporini G (1982) Hormonotherapy of advanced breast carcinoma: comparative evaluation of tamoxifen citrate versus medorxyprogesterone ace- tat. In: Jacobeiii S, Lippman ME, Robustelli della Cuna G (eds) The role of tamoxifen in breast cancer. Raven, New York, p 113Google Scholar
  45. Berg JW (1955) The significance of axillary node levels in the study of breast carcinoma. Cancer 8: 776PubMedGoogle Scholar
  46. Berg JW, Robbins GF (1962) A late look at the safety of aspiration biopsy. Cancer 15: 826PubMedGoogle Scholar
  47. Bergholz M, Schauer A, Reck H, Gregl A (1979) Krebsrisiko bei papillären Proliferationen der Brustdrüse. Arch Klin Chir 348: 157–165Google Scholar
  48. Bergkvist L et al. (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293–297PubMedGoogle Scholar
  49. Berg-Schlosser V, Zimmermann U, Prignitz R, Kleinsorge F, Hess F (1981) Die Bedeutung der postoperativen Strahlenbehandlung zur Senkung der Lokalrezidivrate beim Mammakarzinom. Strahlentherapie 157: 705–712Google Scholar
  50. Bessler W, Weber S (1977) Die Strahlenbehandlung von Knochenmetastasen beim Mammakarzinom. Praxis 66: 140–146PubMedGoogle Scholar
  51. Betzier M (1981) Beispiele für die ambulante Nachsorge: Mammakarzinom. Vorschlag des Tumorzentrums Ulm. MMW 123: 1644Google Scholar
  52. Bindewaith H, Geier G (1980) Mammakarzinom. Stellenwert der Tripel-Diagnostik bei der chirurgischen Therapie. MMW 122: 16–17Google Scholar
  53. Bloom HJG, Richardson WW (1957) Histologie grading and prognosis in breast cancer. A study of 1409 cases which 359 have been followed for 15 years. Br J Cancer 11: 359PubMedGoogle Scholar
  54. Bloom HJG, Richardson WW, Harris EJ (1962) Natural history of breast cancer. Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J 11: 213Google Scholar
  55. Bloom ND, Fishman JH (1983) Tamoxifen treatment failures in hormonally responsive breast cancers. Correlation steroid receptors. Cancer 51: 1190–1194Google Scholar
  56. Blossey HC, Wander HE, Nagel GA, Köbberling J, Kleeberg U (1982) Medoxyprogesteron- acetat in hoher Dosierung beim metastasierenden Mammakarzinom. Onkologie [Sonderheft] 5: 13–16Google Scholar
  57. Blot WJ, Fraumeni JF, Stone BJ (1977) Geographie patterns of breast cancer in the United States. JNCI 59: 1407–1411Google Scholar
  58. Bodgen AE, Griffin TW, Reic SD, Constanza ME, Cobb WR (1984) Prätherapeutische Testung mit dem Nierenkapseltest (“subrenal capsule assay”). In: Seeber S, Osieka R, Sack H, Schönenberger H (Hrsg) Das Resistenzproblem bei der Chemo- und Radiotherapie maligner Tumoren. Karger, Basel (Beiträge Onkologie, Bd 18, S 315 )Google Scholar
  59. Bolmgren J, Jacobson B, Nordenstrom R (1977) Stereotaxic instrument for needle biopsy of the mamma. AJR 129: 121–125Google Scholar
  60. Bonadonna G (1989) Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7: 1380–1397PubMedGoogle Scholar
  61. Bonadonna G, Valagussa P (1987) Current status of adjuvant chemotherapy for breast cancer. Semin Oncol 14: 8–22PubMedGoogle Scholar
  62. Bonadonna G, Veronesi U, Branbilla C et al. (1989) Primary CMF can avoid mastectomy in tumors ≥ 3 cm. Proc ASCO (Abstract 74 ) p 20Google Scholar
  63. Bonneterre J, Coppens H, Maruiac L et al. (1985) Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomised trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 21: 1153PubMedGoogle Scholar
  64. Boquoi E, Kreuzer G (1984) Die Zytodiagnostik der Neoplasie der Brustdrüse. In: Kubli F, von Fournier D (Hrsg) Neue Konzepte der Diagnostik und Therapie des Mammakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 48–53Google Scholar
  65. Borger JJ, Keijser AH (1987) Conservative breast cancer treatment: analysis of cosmetic results and the role of concomitant adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 13: 1173–1177PubMedGoogle Scholar
  66. Bostwick J (1989) Prinzipien bei der Wahl der Lappenplastik zur Rekonstruktion der Brust. In: Bohmert H (Hrsg) Brustkrebs. Organerhaltung und Rekonstruktion. Thieme, Stuttgart, S 258–266Google Scholar
  67. Brun del Re R, Stucki D, Herbst S, Almendral A (1977) Vorgehen bei mammographisch suspekten Veränderungen ohne lokalisierten palpablen Befund. Gynäkol Rundsch 17:85– 87Google Scholar
  68. Brun del Re R, Stucki D, Dickreuter W, Almendral A, Lüscher K, Torhorst J (1981) Erfahrungen mit der neuen automatischen Biopsiepistole fur Tru-Cut-Nadelbiopsie. Gynäkol Rundsch 21: 41–44PubMedGoogle Scholar
  69. Brunner KW (1985) Die internistische Therapie des metastasierenden Mammakarzinoms. In: Büchner Th, Urbanitz D, von de Loo J (Hrsg) Therapie des Mammakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 51–68Google Scholar
  70. Brunner KW (1987) Palliative Tumor-Chemotherapie und Lebensqualität: was ist optimal? Schweiz Med Wochenschr 117: 688–692PubMedGoogle Scholar
  71. Brunner KW (1989) Die Kombinations-Chemotherapie beim metas tasierenden Mammakarzinom. In: Becher R, Höffken K (Hrsg) Die Systemtherapie des Mammakarzinoms. Zuckschwerdt, München, S 114–121Google Scholar
  72. Brunner KW, Harder F, Greiner R, Frost M et al. (1988) Das lokoregionale Rezidiv nach operiertem Mammakarzinom: prognostische Faktoren und therapeutische Konsequenzen. Schweiz Med Wochenschr 118: 1976–1981PubMedGoogle Scholar
  73. Bünemann H (1973) Die Rezidivlokalisation nach Strahlentherapie des Mammakarzinoms. Strahlenther 146: 7–14Google Scholar
  74. Bunker ML, Peters MV (1963) Breast cancer associated with pregnancy or lactation. Am J Obstet Gynecol 85: 312PubMedGoogle Scholar
  75. Burger MM (1973) Surface changes in transformed cells detected by lectins. Fed Proc 32: 91PubMedGoogle Scholar
  76. Calle R, Pilleron JP (1979) Radiation therapy with and without lymphectomy for operable breast cancer. Dis Breast 54: 2Google Scholar
  77. Calle P, Pilleron JP (1982) Nicht verstümmelnde Behandlungsverfahren beim operablen Brustkrebs. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stuttgart, S 207Google Scholar
  78. Calle R, Pilleron JP, Schlienger P, Vilcoq JR (1978) Conservative management of operable breast cancer. Ten years experience at the Foundation Curie. Cancer 42: 2045Google Scholar
  79. Calle R, Vilcoq JR, Zafrani B, Vielh P, Fourquet A (1986) Local control and survival of breast cancer treated by limited surgery followed by irradiation. Int J Radiat Oncol Biol Phys 12: 873–878PubMedGoogle Scholar
  80. Cappelaere P, Querlen D (1980) L’avenir obstetrical des cancereuses aprés traitemenL Gynecologie 31: 329Google Scholar
  81. Carlile T (1981) Breat cancer detection. Cancer 47: 1164–1169PubMedGoogle Scholar
  82. Carrol KK (1975) Experimental evidence of dietary factors and hormone-dependent cancers. Cancer Res 35: 3374Google Scholar
  83. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63: 181PubMedGoogle Scholar
  84. Castiglione M, Goldhirsch A (1989) Lebensqualität bei zytostatischer Chemotherapie: Meßbarkeit und Beurteilung. In: Becher R, Höffken K (Hrsg) Die Systemtherapie des Mammakarzinoms. Zuckschwerdt, München, S 135–140Google Scholar
  85. Cavalli F (1983) Was gibt es Neues auf dem Gebiet der Hormontherapie und der kombinierten Hormono-Chemotherapie? In: Hellriegel KP, Sack H (Hrsg) Bronchialkarzinom, Mammakarzinom. Springer, Berlin Heidelberg New York Tokyo, S 83–114Google Scholar
  86. Cavalli F, Goldhirsch A, Alberto P (1984a) Die SAKK-Erfahrungen mit Aminoglutethimid. In: Nagel GA, Schmidt-Matthiesen H, Drees N (Hrsg) Aminoglutethimid: Ein Antiöstrogen mit Aromatasehemmung. Akt Onkol 9. Zuckschwerdt, München, S 68Google Scholar
  87. Cavalli FA, Goldhirsch A, Joss RA, Brunner KW (1984b) Adriamycin in the treatment of breast cancer: the European experience with particular emphasis on the studies of the Swiss group for clinical cancer research (SAKK). In: Ogawa M, Muggia FM, Rozencweig M (eds) Adriamycin: its expanding role in cancer treatment Exceipta Medica, Amsterdam, p 81Google Scholar
  88. Cheung PS, Yan KW, Alagaratnam TT (1987) The complementary role of fine needle aspiration cytology and tru-cut-needle-biopsy in the management of breast masses. Aus NZ J Surg 57: 615–620Google Scholar
  89. Chlebowski RT, Paroly WS, Pugh RP et al. (1980) Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64: 47PubMedGoogle Scholar
  90. Chu FCH, Lin F, Kim J, Huh SH, Garmatis CJ (1976) Locally recurrent carcinoma of the breast. Results of radiation therapy. Cancer 37: 2677–2681Google Scholar
  91. Ciatto S (1987) Breast cancer diagnosis. (Vortrag gehalten am Postgraduate Course on Breast Cancer, 21st–25th Sept, European School on Oncology, Milan, Italy, Chairman: U. Veronesi )Google Scholar
  92. Citoler P, Zippel HH (1974) Carcinombefall der Mamille bei Mammaearcinomen. Gynäkologe 7: 186Google Scholar
  93. Clarke DH, LG MG, Sarrazin D et al. (1985) Analysis of localregional relapses in patients with early breast cancers treated by excision and radiotherapy. Experience of the Institut Gustave-Roussy. J Radiat Oncol Biol Phys 11: 137–145Google Scholar
  94. Clemmesen J (1977) Survival rates for pre- and postmenopausal Danish women with mammary carcinoma. Acta Radiol CTher) 16: 187–193Google Scholar
  95. Cole MP (1970) Prophylactic compared with therapeutic x-ray artificial menopause. In: Hoslin CAF, Gleave EM (eds) The clinical management of advanced breast cancer. 2nd Tenovus Workshop on breast cancer. Alpha Omega Alpha, Cardiff, pp 2–11Google Scholar
  96. Committee for Radiation Oncology Studies (1976) Research plan for radiation ocnology. Radiation therapy and chemotherapy. Cancer 37: 2093–2107Google Scholar
  97. Consensus Meeting (1979) Therapie des metastasierenden Mammakarzinoms in Abhängigkeit vom Hormonrezeptorstatus. National Institute of Health. Bethesda, WashingtonGoogle Scholar
  98. Cooke J, Hansell DM, Parsons C (1987) Mammography. Wolfe Medical, London Cooper RA (1989) Mammography. Clin Obstet Gynecol 32 /4: 768–785Google Scholar
  99. Cowan LD, Gordis L, Tonascia JA et al. (1981) Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 114: 209PubMedGoogle Scholar
  100. Cutler SJ, Zippin C, Asire AJ (1969) The prognostic significance of palpable lymph nodes in cancer of the breast Cancer 23: 243Google Scholar
  101. Cutler SJ, Devesa SS, Barclay THC (1976) The magnitude of the breast cancer problem. In: Arnault G et al. (eds) Breast cancer. A multidisciplinary approach. Springer, Berlin Heidelberg New York, p 1Google Scholar
  102. Dalen A van, Dupree HW, Heering KJ, van der Linde DL (1987) The determination of CA 15-3 during therapy monotoring of breast cancer patients. In: Klapdor R (ed) New tumormarkers and their monoclonal antibodies. Thieme, Stuttgart, pp 105–112Google Scholar
  103. Dall’Olmo CA, Ponka JL, Horn RC, Riu R (1975) Lobular carcinoma of the breast in situ. Arch Surg 110: 537–542PubMedGoogle Scholar
  104. Day ED (1965) The immunochemistry of cancer. Thomas, Springfield De Matteis A, Buonaguro F, Labonia V, Zarilli B (1979) Terapia con tamoxifene del cancro della mamella al IV stadio. Rass Int Clin Ter 59: 1548Google Scholar
  105. De Waal IC, Baltzer J, Muthmann-Nagy C, Schmid M, Zander J (1987) Zur Wertigkeit von Palpation und Mammographie beim primären Mammakarzinom. Geburtshilfe Frauen- heilkd 47: 93–95Google Scholar
  106. De Waard F (1978) Recent time trends in breast cancer incidence. Prev Med 7: 160–167Google Scholar
  107. De Waard F, Collette HJA, Rombach JJ et al. (1984) The DOM-project for the early detection of breast cancer. Utrecht, The Netherlands, J Chronic Dis 37: 1Google Scholar
  108. Del Villano BC (1985) Tumormarkers in cancer diagnosis - present and future. In: Klietman W (Hrsg) Aktuelle Tumormarker. Schattauer, Stuttgart, S 9Google Scholar
  109. Denecke H et al. (1986) Technik und Methoden bei regionaler Leberperfusion. In: Schölmerich P, Kleinsorge H (Hrsg) Apparative Technik und Pharmakotherapie. Fischer, Stuttgart, S 107–116Google Scholar
  110. Der Hagopion RP, Zaworski PC, Sugerbaker EV, Ketcham AS (1981) Management of locally recurrent breast cancer adjacent to prosthetic implants. Am J Surg 141: 590Google Scholar
  111. Dexeus S, Serrat X, Tolosa HA (1982) Der Einfluß von Schwangerschaft und Laktation auf die Prognose beim Mammakarzinom. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stuttgart, S 153Google Scholar
  112. Di Peitro S, Berfario L, Piva L (1980) Prognosis and treatment of loco-regional breast cancer recurrences: critical considerations on 120 cases. Tumori 66: 331–338Google Scholar
  113. Diehl V (1980) Nachsorge für Krebspatienten. Med Klin 75: 602–608PubMedGoogle Scholar
  114. Donegan WL (1967) Staging and end results. In: Spratt J, Donegan W (eds) Cancer of the breast Saunders, Philadelphia, p 117Google Scholar
  115. Donegan WL, Perez-Mesa CM (1972) Lobular carcinoma - an indication for elective biopsy of the second breast Ann Surg 176: 178–187Google Scholar
  116. Dood GD (1977) Present status of thermography, ultrasound and mammography in breast cancer. Cancer 39: 2796–2805Google Scholar
  117. Dood GD (1984) Mammography: state of the art Cancer 53: 652Google Scholar
  118. Dowden RV, Horton CE, Rosato FE (1979) Reconstruction of the breast after mastectomy. Surg Gynecol Obstet 149: 109PubMedGoogle Scholar
  119. Dowlatshahi K, Jokich PM, Schmidt R, Bibbo M, Dawson PJ (1987) Cytologic diagnosis of occult breast lesions using stereotaxic needle aspiration. A preliminary report. Arch Surg 122: 1343–1346Google Scholar
  120. Dowle CS, Mitchell A, Elston CW, Roebuck EJ, Hinton CP, Holliday H, Blamery RW (1987) Preliminary results of the Nottingham breast self-examination education programme. Br J Surg 74: 217–219PubMedGoogle Scholar
  121. Droese M (1981) Punktionszytologie der Brustdrüse. In: Zenker R, Deucher F, Schink W (Hrsg) Chirurgie der Gegenwart, Bd 3. Urban & Schwarzenberg, München, S 45–50Google Scholar
  122. Early Breast Cancer Trialists Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28896 women. N Engl J Med 319: 1681–1692Google Scholar
  123. Edeiken S (1988) Mammography and palpable cancer of the breast. Cancer 61: 263–265PubMedGoogle Scholar
  124. Egan RL (1960) Experience with mammography in a tumor institution. Evaluation of 1000Google Scholar
  125. studies. Radiology 75:894–900Google Scholar
  126. Egan RL (1988) Breast imaging: diagnosis and morphology of breast disease. Saunders, PhiladelphiaGoogle Scholar
  127. Elston GW, Cotton RE, Davies CJ, Blarney RW (1987) Comparison of the use of the “tru-cut” needle and fine needle aspiration cytology in the preoperative diagnosis of carcinoma of the breast. Histopathology 2: 239–254Google Scholar
  128. Engel JN, Ahmann DL, Green SJ et al. (1981) Randomized clinical trial of diethylstillbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16Google Scholar
  129. Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E (1981) Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48:876– 882Google Scholar
  130. Fallenius AG, Auer G, Carstensen JM (1988) Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 62: 331–341PubMedGoogle Scholar
  131. Feichter GE, von Founder D, Kaufmann M (1989) S-Phase fractions and DNA ploidy a prognostic factors in breast cancer. In: Kubli F, von Fournier D, Bauer M, Junkerman H, Kaufmann M (eds) Breast diseases. Springer, Berlin Heidelberg New York Tokyo, pp 43–47Google Scholar
  132. Feig SA (1984) Radiation risk from mammography: is it clinically significant? AJR 143:469– 475Google Scholar
  133. Feig SA (1986) The role of new imaging modalities in staging and follow-up of breast cancer. Semin Oncol 13: 402–414PubMedGoogle Scholar
  134. Feig SA, Schwartz GE (1984) Prognostic pathologic factors among breast cancer detection on screening by mammography. In: Brünner S, Langfeld B, Andersen PE (eds) Early detection of breast cancer. Springer, Berlin Heidelberg New York Tokyo, p 148Google Scholar
  135. Feldman JG, Carter AC, Nicastri AD, Hosat ST (1981) Breast self-examination. Relationship to stage of breast cancer at diagnosis. Cancer 47: 2740–2745Google Scholar
  136. Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4: 237PubMedGoogle Scholar
  137. Fisher B (1973) Cooperative clinical trials in primary breast cancer: a critical appraisal. Cancer 31: 1271–1286PubMedGoogle Scholar
  138. Fisher B (1980) Laboratory and clinical research in breast cancer - a personal adventure. The Davia A. Karnofsky Memorial Lecture. Cancer Res 40: 3863–3874PubMedGoogle Scholar
  139. Fisher B (1989) Entwicklung, Technik und Ergebnisse der brusterhaltenden Therapie. In: Bohmert H (Hrsg) Brustkrebs. Organerhaltung und Rekonstruktion. Thieme, Stuttgart New York, S 42–63Google Scholar
  140. Fisher B, Fisher ER (1966) Transmigration of lymph nodes by tumor cells. Science 152: 1397–1398PubMedGoogle Scholar
  141. Fisher B, Slack NH (1970) Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 131: 79–88PubMedGoogle Scholar
  142. Fisher B, Slack NH, Bross IDJ (1969) Cancer of the breast. Size of neoplasm and prognosis. Cancer 24: 1071Google Scholar
  143. Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528–534PubMedGoogle Scholar
  144. Fisher B, Montagne E, Remond C et al. (1977) Comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer 39: 2827PubMedGoogle Scholar
  145. Fisher B, Womark N, Redmond C, Deutsch M, Fisher E (1981) Comparison of radical mastectomy with alternative treatments II. The clinical and biological significance of Medical-Center Breast cancer. Cancer 48: 1863Google Scholar
  146. Fisher B, Bauer M, Wickerham L, Redmond C, Fisher E (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer - an NSABP update. Cancer 52: 1551–1557PubMedGoogle Scholar
  147. Fisher B, Bauer M, Margolese R et al. (1985a) Five-year results of randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312: 665–673PubMedGoogle Scholar
  148. Fisher B, Redmond C, Fisher ER et al. (1985b) Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312: 674–681PubMedGoogle Scholar
  149. Fisher B, Brown A, Wolmark N et al. (1987) Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106: 649–654Google Scholar
  150. Fisher B, Redmond C, Dimitrov NV et al. (1989a) A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320: 473–78PubMedGoogle Scholar
  151. Fisher B, Redmond C, Poisson R et al. (1989b) 8 year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320: 822–828PubMedGoogle Scholar
  152. Fisher ER (1978) The pathologist’s role in the diagnosis and treatment of invasive breast cancer. Surg Clin North Am 58: 705–721PubMedGoogle Scholar
  153. Fisher ER, Gregorio R, Redmond C et al. (1975a) Pathologie findings from the national surgical adjuvant breast project (Protocol no. 4). I: Observations concerning the multi-centricity of mammary cancer. Cancer 35: 247–254Google Scholar
  154. Fisher ER, Gregorio RM, Fisher B (1975b) The pathology of invasive breast cancer. Cancer 36: 1PubMedGoogle Scholar
  155. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B (1978a) Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42: 2025–2031PubMedGoogle Scholar
  156. Fisher ER, Paleka A, Rockette H, Redmond G, Fisher B (1978b) Pathologic findings from the national surgical adjuvant breast project (Protocol Nr. 4). V. Significance of axillary node micro- and macrometastases. Cancer 42: 2032–2038Google Scholar
  157. Fisher ER et al. (1986) Pathologic findings from the national surgical adjuvant breast project (Protocol 6). II. Relation of local breast recurrence to multicentricity. Cancer 57:1717– 1724Google Scholar
  158. Fletcher GH (1972) Local results of irradiation in the primary management of localized breast cancer. Cancer 29: 545PubMedGoogle Scholar
  159. Fletcher GH (1980) Textbook of radiotherapy, 3rd edn. Lea & Febiger, Philadelphia Fletcher GH, Montague ED (1978) Dose adequate irradiation of the internal mammary chain and supraclavicular nodes in prove survival rates? Int J Radiat Oncol Biol Phys 4:481–492Google Scholar
  160. Forrest APM (1977) Conservative local treatment of breast cancer. Cancer 39: 2813–2821PubMedGoogle Scholar
  161. Forrest-Report (1987) Breast cancer screening report to the Health Ministers of England, Wales, Scotland and Northern Irland by a Working Group. H.M. Stationery Office, London. Lancet 1:543–544, 575–576Google Scholar
  162. Foster RS, Constanza MC (1984) Breast self-examination practices and breast cancer survival. Cancer 53: 999–1005PubMedGoogle Scholar
  163. Fouraier D von, Kuttig H, Kubli F, Prager P, Stolpe H, Maier A, Hüter J (1976) Wachstums-geschwindigkeit des Mammakarzinoms und röntgenologische “Frühdiagnosen”. Strahlentherapie 151: 318Google Scholar
  164. Fournier D von, zum Winkel K, Kuttig H, Kubli F (1986) Strahlentherapie als adjuvante Maßnahme beim Mammakarzinom. In: Kadach U, Kaufmann M, Kubli F (Hrsg) Hormone Antihormone Zytostatika zur adjuvanten Therapie des Mammakarzinoms. Zuck- schwerdt, München, S 82–97Google Scholar
  165. Fournier D von, Junkermann H, Krapfl E, Anton HW, Stolz W, Heep J (1989a) Überblick über Therapieformen gutartiger Brusterkrankungen. Gynäkologe 22: 246–254Google Scholar
  166. Fournier D von, Müller A, Junkermann H, Schlegel W (1989b) Status of radiotherapy after ablative and breast-preserving treatment of breast cancer. In: Kubli F, von Foumier D, Bauer M, Junkermann H, Kaufmann M (eds) Breast diseases. Breast-conserving therapy, non-invasive lesions, mastopathy. Springer, Berlin Heidelberg New York Tokyo, pp 240– 261Google Scholar
  167. Fowble B (1989) Conservative surgery and radiation in the treatment of stage I and II breast cancer. Astro Refresher Course No. 207Google Scholar
  168. Frable WJ (1984) Needle aspiration of breast. Cancer 53: 671–676PubMedGoogle Scholar
  169. Frank JW, Mai V (1985) Breast self-examination in young women: more harm than good? Lancet 2: 654–657PubMedGoogle Scholar
  170. Frentzel-Beyme R, Leutner R, Wagner G, Wiebelt H (1979) Krebsatlas der Bundesrepublik Deutschland. Springer, Berlin Heidelberg New YorkGoogle Scholar
  171. Friedberg V (1980) Die operative Therapie des Mammakarzinoms. Mittelrhein. Tagung für Geburtshilfe u Gynäkologie 13–15 Juni, Rüsselsheim (Referat 152 )Google Scholar
  172. Frischbier HJ, Bahnsen J (1989) Die Screening-Mammographie: Ihre Bedeutung für die Senkung der Brustkrebsmortalität und Möglichkeiten der praktischen Umsetzung. Hamburger Ärztebl 1989: 121–131Google Scholar
  173. Frischbier HJ, Lohbeck HU (1977) Frühdiagnostik des Mammakarzinoms. Klinische, röntgenologische, therapeutische und zytologische Untersuchungsmethoden und ihre Wertigkeit Thieme, StuttgartGoogle Scholar
  174. Gallager HS (1984) Pathologie type of breast cancer: their prognosis. Cancer 53: 623PubMedGoogle Scholar
  175. Gardellin G, Natale F, Perm B (1986) Localizzazione preoperativa delle lesioni mammarie non palpabili. Radiol Med (Torino) 72: 199–203Google Scholar
  176. Gelber RD, Goldhirsch A, Gastiglione M, Price K et al. (1987) Time without symptoms and toxicity (TWiST): a quality-of-life oriented endpoint to evaluate adjuvant therapy. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer V. Grune & Stratton, Orlando FL, pp 455–465Google Scholar
  177. Gent HJ, Sprenger E, Dowlatshahi K (1986) Stereotaxic needle localization and cytological diagnosis of occult breast lesions. Ann Surg 204: 580–584PubMedGoogle Scholar
  178. George SI, Hoogstraten B (1978) Prognostic factors in the initial response to therapy by patients with advanced breast cancer. JNCI 4: 731Google Scholar
  179. Gershon-Cohen J, Inglebey H, Berger SM, Forman M, Curcio BM (1967) Mammographie screening for breast cancer. Results of an ten year survey. Radiology 88: 663–667Google Scholar
  180. Gillis DA, Dockerty MB, Clagett OT (1969) Preinvasive intraductal carcinoma of the breast. Surg Gynecol Obstet 110: 555–562Google Scholar
  181. Glick JH (1989) Closing summary and outlook. In: Senn HJ, Goldhirsch A, Gelber RD, Osterwalder B (eds) Adjuvant therapy of primary breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 283–292Google Scholar
  182. Gohagan JK, Spitznagel EL, McCrate MM, Frank TB (1984) ROC analysis of mammography and palpation for breast screening. Invest Radiol 19: 587–592PubMedGoogle Scholar
  183. Goldhirsch A, Gelber RD (1987) For the Ludwig Breast Cancer Study Group: adjuvant therapy for breast cancer: the Ludwig Breast Cancer Trials. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, pp 297–310 Goldhirsch A, Gelber RD (1988) Treatment of overt metastatic breast cancer. Bailli cancer. Baillieres Clin Oncol 2: 215–229Google Scholar
  184. Granitzka S (1990) Motivationen zur Brustrekonstruktion bei Frauen mit Ablatio mammae. 1. Jahrestagung der AWO. Internationales Symposium über neue Entwicklungen zur Erhaltung und Wiederherstellung der Brust beim Mamma-Karzinom. Berlin 23.–25. 2. 90Google Scholar
  185. Greenwald P, Nasca PC, Lawrence CE, Horton J, McGarrah RP, Gabriele T, Carlton K (1978) Estimated effect of breast self-examination and routine physician examinations on breast cancer mortality. N Engl J Med 299: 271–273PubMedGoogle Scholar
  186. Griffith CN, Kern WH, Mikkelsen WP (1986) Needle aspiration cytologic examination in the management of suspicious lesions of the breast. Surg Gynecol Obstet 162: 142–144PubMedGoogle Scholar
  187. Gros R (1987) Die weibliche Brust, de Gruyter, Berlin, S 71Google Scholar
  188. Gross R (1986) Tumormarker: Eine kritische Zwischenbilanz. Dtsch Ärztebl 83: 2289Google Scholar
  189. Haagensen CD (1971) Diseases of the breast, 2nd edn. Saunders, Philadelphia, p 617Google Scholar
  190. Haagensen CD (1986) Disease of the breast, 3rd edn. Saunders, PhiladelphiaGoogle Scholar
  191. Hackelöer BJ (1989) Einsatzplan für die Ultrasonographic. In: Benz J (Hrsg) Mammakarzinom. Aktueller Stand der Diagnostik. Mamma-Symposium Winterthur 1988. Bäbler, BernGoogle Scholar
  192. Hahn P, Hallberg O, Schmierer LB (1981) Combination of clinical examination, mammography and aspiration cytology in the diagnosis of carcinoma of the breast Strahlenther 156: 457–459Google Scholar
  193. Hähnel R, Woodings T, Vivian AB (1979) Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671PubMedGoogle Scholar
  194. Haller U (1987) Breast reconstruction following mastectomy. In: Takagi S, Friedberg V, Haller U, Knapstein PG, Sevin BU (eds) Gynecologic oncology, surgery and urology. Proc of the 3rd Int Symp, Japan. Central Foreign Books Ltd, Tokyo, pp 46–59Google Scholar
  195. Halsted WS (1894) The results of operations for the cure of cancer of the breast performed at the John Hopkins Hospital from June 1889 to January 1894. Arch Surg 20: 497Google Scholar
  196. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461PubMedGoogle Scholar
  197. Hammond S, Keyhani-Rotagha S, OToole RV (1986) Statistical analysis of fine needle aspiration cytology of breast A review of 678 cases plus 4265 cases from the literature. Acta Cytol 31: 276–280Google Scholar
  198. Handley RS, Thackray AC (1974) Invasion of internal mammary lymph nodes in carcinoma of the breast Br Med J 1: 61Google Scholar
  199. Harder F, Torhorst J, Hünig R, Walther E (1981) Brusterhaltende Behandlung beim Mammakarzinom mit einem Durchmesser von bis zu 2,0 cm und histologisch tumorfreier Axilla. Schweizerische Arbeitsgruppe für Klinische Krebsforschung (SAKK). Protokoll Nr. 22 /81Google Scholar
  200. Harland SJ, Waxman JH, Rees L, Ford HT et al. (1985) The treatment of premenopausal patients with breast cancer with buserelin nasal spray. Br J Cancer 52: 421Google Scholar
  201. Harris JR, Hellmann S, Silen W (1983) Conservative management of breast cancer. New surgical and radiotherapeutic techniques. Lippincott, PhiladelphiaGoogle Scholar
  202. Harris JR, Abram R, Schnitt S, Connolly J, Silver B, Come S, Henderson IC (1985) Current status of conservative surgery and radiotherapy as primary local treatment for early carcinoma of the breast Breast Cancer Res Treat 5: 245–255Google Scholar
  203. Harvey HA, Lipton A, White DS, Santen RJ, Boucher AE, Shafik AS, Dixon RJ (1982) Crossover comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res [Suppl] 42: 3451Google Scholar
  204. Harvey HA, Lipton A, Max D (1986) LH-RH-agonist treatment of breast cancer: a phase II study in the USA. Eur J Cancer Clin Oncol 22: 724Google Scholar
  205. Hayward JL (1983) Prospective studies, the Guy’s Hospital trials on breast conservation. In: Harris JR, Hellman S, Silen WJB (eds) Conservative management of breast cancer. Lippincott, Philadelphia, pp 77–90Google Scholar
  206. Heberer G, Wilmanns W, Günther B, Sauer H (1981) Das Mammakarzinom - operative und interdisziplinäre Aspekte. Chirurg 52: 212PubMedGoogle Scholar
  207. Heidenreich W, Majewski A (1986) Klinik des Cystosarcoma phylloides. Gynäkol Praxis 10: 489Google Scholar
  208. Heilmann JHP (1979) Die Problematik des Mammakarzinoms aus radiologischer Sicht. Strahlentherapie 155: 588–595PubMedGoogle Scholar
  209. Heilmann HP (1987) Aufgabe der Strahlentherapie im Rahmen der interdisziplinären Therapie des Brustkrebs. In: Interdisziplinäre Therapie des Mammakarzinoms. Meducation Foundation Clyancourt Corporation Cham, S 242–257Google Scholar
  210. Hellman S, Harris JR, Canellos GP, Fisher B (1982) Cancer of the breast. In: DeVita, Hellman, Rosenberg (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, pp 914–970Google Scholar
  211. Henderson IC (1984) Chemotherapy for advanced disease. In: Bonadonna G (ed) Breast cancer. Diagnosis and management. Wiley, New York, pp 247–280Google Scholar
  212. Henderson IC (1987a) Chemotherapy for advanced disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases. Lippincott, Philadelphia, pp 428–479Google Scholar
  213. Henderson IC (1987b) V. Mitoxantrone for advanced breast cancer: comparisons with other standard agents. In: Mouridsen HT, Zalmen AA (eds) The role of mitoxantrone in malignant diseases. PharmaLibri, Chicago, pp 49–66Google Scholar
  214. Henderson IC (1987c) Adjuvant systemic therapy of early breast cancer. In: Harris JR, Hellmann S, Henderson IC, Kinne DW (eds) Breast diseases. Lippincott, Philadelphia, pp 324–353Google Scholar
  215. Henderson IC, Harris JRT, Klune DW, Hellman S (1989) Cancer of the breast In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer, principles & practice of oncology, 3rd edn. Lippincott, Philadelhia, pp 1197–1268Google Scholar
  216. Hermanek R, Bünte H (1972) Die intraoperative Schnellschnittuntersuchung: Methoden und Konsequenzen. Urban & Schwarzenberg, München, S 19–78Google Scholar
  217. Heusser L, Spratt JS, Polk HC (1979) Growth rates of primary breast cancer. Cancer 43: 1888Google Scholar
  218. Heyden S, Amgwerd R, Gloor F, Wild R, Bruderer E, Metzler B (1974) Ergebnisse von Mamma-Vorsorgeuntersuchungen bei 1000 berufstätigen Frauen im Kanton St. Gallen. Schweiz Med Wochensehr 104: 1525–1529Google Scholar
  219. Hoeffken W (1983) Mammographie. In: Feiereis H et al. (Hrsg) Brustkrebs der Frau. Marseille, München, S 65–82Google Scholar
  220. Hoeffken W (1984) Diagnostische Maßnahmen zur Früherkennung des Mammakarzinoms. In: Kubli F, von Fournier D (Hrsg) Neue Konzepte der Diagnostik und Therapie des Mammakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 29–32Google Scholar
  221. Höffken K, Miller AA, Miller B, Becher R et al. (1987) Niedrigdosierte Aminoglutethimid- Therapie ohne Corticol-S ubstitution beim metastasierenden Mammakarzinom in der Postmenopause. Med Klin 81: 638Google Scholar
  222. Höffken K, Oesterdickhoff C, Becher R, Callies R et al. (1989) LH-RH-agonist treatment with buserelin in premenopausal patients with advanced breast cancer. A phase H study. Cancer Ther Control 1: 13–20Google Scholar
  223. Hoffmann L, Heinzerling D, Schäfer E, Scheele A, Klapdor R (1987) CA 15–3 and CEA monitoring in the evaluation of the course of metastasizing breast cancer. In: Klapdor R (ed) New tumormarkers and their monoclonal antibodies. Thieme, Stuttgart, pp 74–79Google Scholar
  224. Holland R, Hendriks JHCL, Mravuanac M (1983) Mammographically occult breast cancer. A pathologic and radiologic study. Cancer 52: 1810–1819Google Scholar
  225. Holleb AJ, Farrow JH (1962) Breast cancer and pregnancy. A report of 283 cases. Surg Gynecol Obstet 115: 65PubMedGoogle Scholar
  226. Homer MJ (1985) Breast imaging: pitfalls, controversies, and some practical thoughts. Radiol Clin North Am 23 /3: 459–472PubMedGoogle Scholar
  227. Horsley JS, Newsome HH, Brown PW, Neifeld JP, Terz JJ, Lawrence W jr (1982) Medical adrenalectomy in patients with advanced breast cancer. Cancer 49: 1145–1149PubMedGoogle Scholar
  228. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD et al. (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776PubMedGoogle Scholar
  229. Hortobagyi G, Ames F, Buzdar A (1987) Effective multidisciplinary therapy of inoperable stage in breast cancer. Proc Am Soc Clin Oncol 6: 64Google Scholar
  230. Host H, Brennhovd IO (1977) The effect of post-operative radiotherapy in breast cancer. Int J Radiat Oncol Biol Phys 2: 1061–1067PubMedGoogle Scholar
  231. Howe GR (1984) Epidemiology of radiogenic breast cancer. In: Boice JD jr, Fraumeni JF jr (eds) Radiation carcinogenesis: epidemiology and biological significance. Raven, New York, pp 119–129Google Scholar
  232. Hughes LE, Forbes JF (1978) Early breast cancer, part I: Surgical pathology and preoperative assessment. Br J Surg 65: 753–763Google Scholar
  233. Huguley CM, Brown RL (1981) The value of breast self-examination. Cancer 47:989– 995Google Scholar
  234. Huhn FO, Stock G (1977) Zur Frage eingeschränkter sowie begrenzter Behandlungsmöglichkeiten von Mammakarzinomen. Befunddokumentation an 400 Operationspräparaten. Geburtshilfe Frauenheilkd 37: 686PubMedGoogle Scholar
  235. Hüter J (1990) Die wiederaufbaugünstige Mastektomie. 1. Jahrestagung der AWO, Int Symp über neue Entwicklungen zur Erhaltung und Wiederherstellung der Brust beim Mamma-Ca. Berlin 23.–25. 2. 90Google Scholar
  236. Hüter J, Meyer-Menk W, Klingemann H (1984) Die subkutane Reduktionsmastektomie. In: Kubli F, Fournier D von (Hrsg) Neue Konzepte der Diagnostik und Therapie des Mammakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 108–116Google Scholar
  237. Hüter-Löliger S (1986) Rekonstruktion von Areola und Mamille. In: 97. Tagung der Nordwestdeutschen Gesellschaft für Gynäkologie und Geburtshilfe. Alete Wissenschaftlicher Dienst, Hildesheim, S 40–42Google Scholar
  238. Hutter RVP (1980) The influence of pathologic factors on breast cancer management. Cancer 46: 961PubMedGoogle Scholar
  239. Huvos AG, Hutter RVP, Berg JW (1971) Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 173: 44–46PubMedGoogle Scholar
  240. Illiger HJ (1981) Aufgaben, Konzepte und Praxis der Tumornachsorge aus der Sicht des Klinikers. In: Hartwich (Hrsg) Aktuelle internistische Tumortherapie. Akt Onkol 2:15– 25, Zuckschwerdt, München (Aktuelle Onkologie 2, S 15.. 25 )Google Scholar
  241. Ingersleben G von, Souchon R, Brand U, Fitzner R (1987) CA 15.3 in comparison with CEA in the follow-up and therapy control of breast carcinoma - new aspects. In: Klapdor R (ed) New tumormarkers and their monoclonal antibodies. Thieme, Stuttgart, pp 113–117Google Scholar
  242. Ingle JN, Ahmann DEL, Green SJ et al. (1981) Randomized clinical trial df diethystilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16 - 21PubMedGoogle Scholar
  243. Jacquillat CI, Weil M, Baillet F, Auclerc G, Khayat D, Auclerc MS, Facchini T (1987) Pre-operative (Neoad) chemotherapy and radiotherapy in breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, New YorkGoogle Scholar
  244. Jakesz R, Kies A, Kolb R, Reiner G, Assmann H, Spona J (1982) Oestrogen- und Proge- steronrezeptoren beim primären Mammakarzinom. In: Jonat W, Maass H (Hrsg) Stero- idhormonrezeptoren im Karzinomgewebe. Enge, Stuttgart, S 31Google Scholar
  245. Jenny J, Schreiner W, Pedio G, Otto R (1985) Epidemiologie und Diagnostik des Mamma-karzinoms. In: Jenny I (Hrsg) Die Brustdrüse, Anatomie, Physiologie, Klinik, Histopathologic und Zytologie unter besonderer Berücksichtigung der möglichst frühen Erfassung des Mammakarzinoms. Hug, Zürich, S 19–38Google Scholar
  246. Jonat W, Maass H (1982) Steroidhormonrezeptoren im Karzinomgewebe. Enke, StuttgartGoogle Scholar
  247. Jonat W, Maass H (1983) Steroidrezeptor-Bestimmung und Hormontherapie. In: Feiereis H, Grewe HE, Johannigmann J et al. (Hrsg) Brustkrebs der Frau. Marseille, München, S 161Google Scholar
  248. Jungi WF (1987) Die Chemotherapie des rezidivierenden metaslasierenden Mammakarzinoms. Gynäkol Praxis 11: 691–699Google Scholar
  249. Jungi WF (1989) Die zytostatische Monochemotherapie einschließlich neuer Substanzen. In: Becher R, Höffken K (Hrsg) Die Systemtherapie des Mammakarzinoms. Zuckschwerdt, München, S 107–113Google Scholar
  250. Junkermann H (1989) Diagnostik gutartiger Brusterkrankungen. Gynäkologe 22: 226–229PubMedGoogle Scholar
  251. Kaufmann M (1983) Biochemische prognostische Faktoren beim Mammakarzinom. In: Kubli F, Nagel GA, Kadach U, Kaufmann M (Hrsg) Neue Wege in der Brustkrebsbehandlung. Zuckschwerdt, München (Aktuelle Onkologie 8, S 46–61 )Google Scholar
  252. Kaufmann M (1988) Consensus-Development Konferenz zur Therapie des metastasierten Mammakarzinoms: Leitlinien zur palliativen Behandlung. MMW 130: 93–102Google Scholar
  253. Kaufmann M, Schmid H (1987) Mitoxantron in Kombination mit Prednimustin. In: Wimanns W, Possinger K (Hrsg) FAC Mitoxantron II. Futuramed, München, S 1425– 1428Google Scholar
  254. Kaufmann M, Feichter GE, Nhila A, Klinga K, Abel U (1988a) Flow-zytophotometrische Parameter, Hormonrezeptoren und axillärer Lymphknotenstatus als Prognosefaktoren beim primären Mammakarzinom. Geburtshilfe Frauenheilkd 48: 705–709Google Scholar
  255. Kaufmann M, Schmid H, Kiesel L, Klinga K (1988b) GnRH-Agonisten ( Zoladex)-Therapie bei prämenopausalen Frauen mit metastasierendem Mammakarzinom. Geburtshilfe Frauenheilkd 48: 528–532Google Scholar
  256. Kaufmann M, Jonat W, Maass H, Bastert G, Kubli F (1988c) Adjuvante Therapie des operablen Mammakarzinoms. Gynäkol Prax 12: 523–530Google Scholar
  257. Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Jänicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H, Strunz P, Schachner-Wünschmann E, Bastert G, Maass H (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7, 8: 1113–1119PubMedGoogle Scholar
  258. Kindermann G (1977) Uber Definition, Diagnostik und Behandlung der sog. “Frühfalle” des Mammakarzinoms. Geburtshilfe Frauenheilkd 37: 829PubMedGoogle Scholar
  259. Kindermann G (1985) Diagnostic value of galactography in the detection of breast cancer. In: Zander J, Baltzer J (eds) Early breast cancer. Springer, Berlin Heidelberg New York, p 136Google Scholar
  260. Kindermann G (1986) Histopathologic der Mammakarzinome: Diagnostisch/prognostische Hüfe für die Klinik. Gyne 7: 12–17Google Scholar
  261. Kleinberg DL (1987) Prolactin and breast cancer. N Engl J Med 316: 269PubMedGoogle Scholar
  262. Klinga K, Kaufmann M, Runnebaum B, Kubli F (1982) Steroidhormonrezeptoren beim Mammakarzinom. Dtsch Med Wochenschr 107: 313–315PubMedGoogle Scholar
  263. Knabbe C, Lippmann ME, Wakefield L et al. (1987) Evidence that TGF-Beta is a hormonally regulated negative growth factor in human breast cancer. Cell 48: 417–428PubMedGoogle Scholar
  264. Knapstein PG, Friedberg V (1987) Plastische Chirurgie in der Gynäkologie. Thieme, Stuttgart, S 50Google Scholar
  265. Kogelnik HD (1984) Die primäre und postoperative kurative Radiotherapie beim Mammakarzinom. Speculum 2: 10–16Google Scholar
  266. Köhle K, Simons C, Urban H (1979) Zum Umgang mit unheilbar Kranken. In: Uexküll Th von (Hrsg) Lehrbuch der psychosomatischen Medizin. Urban & Schwarzenberg, München, S 812Google Scholar
  267. Komaki RK, Cox JD, Kister SJ, Gump FE, Estabrook A (1990) Stage I and II breast carcinoma: treatment with limited surgery and radiation therapy versus mastectomy. Radiology 174: 255–257PubMedGoogle Scholar
  268. Korenmann SG (1980) Oestrogen window hypothesis of the etiology of breast cancer. Lancet 1: 700Google Scholar
  269. Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G, Sarrazin D (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49: 709–715PubMedGoogle Scholar
  270. Kouchoukos NT, Ackerman LV, Butcher HP (1967) Prediction of axillary nodal metastases from the morphology of primary mammary carcinomas. Guide to operative therapy. Cancer 20: 948–966Google Scholar
  271. Kreienberg R (1985) Aktuelle Marker beim Ovarialkarzinom (CA 125). In: Klietmann W (Hrsg) Aktuelle Tumormarker. Schattauer, Stuttgart, S 39Google Scholar
  272. Kreuzer G, Boquoi E (1974) Die Tripeldiagnostik gut- und bösartiger Mammatumoren. Geburtshilfe Frauenheilkd 34: 279–286PubMedGoogle Scholar
  273. Kreuzer G, Boquoi E (1981) Zytologie der weiblichen Brustdrüse. Thieme, Stuttgart, S 18– 21Google Scholar
  274. Kreuzer G, Zajicek J (1972) Cytologie diagnosis of mammary tumors from aspiration biopsy smears. HI. Studies on 200 carcinomas with false negative or doubtful cytologic reports. Acta Cytol (Baltimore) 16: 249–252Google Scholar
  275. Krokowski E (1964) Betrachtung zur Dynamik des Geschwulstwachstums. Krebsforsch Krebsbekämpfung 5: 189Google Scholar
  276. Kübler HC, Kühn W, Rummel HH, Kaufmann M, Klinga K (1989) Immuncytochemische Oestrogenrezeptorbestimmung beim metastasierenden Mammakarzinom. Arch Gynecol Obstet 245/1–4: 702–704Google Scholar
  277. Kübler-Ross E (1969) Interviews mit Sterbenden. Kreuz, StuttgartGoogle Scholar
  278. Kubli F, von Fournier D, Kaufmann M, Lammers G, Bothmann GA, Drings P (1978) Praxis der onkologischen Nachsorge beim Genital- und Mammakarzinom. Manual der Universitätsfrauenklinik, HeidelberegGoogle Scholar
  279. Kubli F, Lorenz U, Rüttgers H (1982) Prognose der Patientin mit Mammacarcinom und chirurgische Rekonstruktion nach Ablatio. 12. Tagung der Vereinigung der Dtsch Plastischen Chirurgen, Frankfurt, SeptemberGoogle Scholar
  280. Kümmerle F, Schreiber HL, Lilie H (1983) Medizinische und juristische Aspekte der Aufklärung bei Tumorpatienten. In: Fischer J (Hrsg) Taschenbuch der Onkologie. Urban & Schwarzenberg, München, S 161–171Google Scholar
  281. Kurtz JM (1990) Zur Frage des Risikos der Entwicklung eines kontralateralen Mammakarzinoms. 1. Jahrestagung der AWO. Int Symp über neue Entwicklungen zur Erhaltung und Wederherstellung der Brust beim Mammakarzinom. Berlin 23.–25. 2. 90Google Scholar
  282. Kurtz JM, Amalric R, Delouehe G, Pierquin B, Roth J, Spitalier JM (1987) The second ten years: long-term risks of breast conservation in early breast cancer. Int J Radiat Oncol Biol Phys 13: 1327–1332PubMedGoogle Scholar
  283. Kurtz JM, Amalric R, Brancone H, Ayme Y, Spitalier JM (1988) Results of wide excision for mammary recurrence after breast-conserving therapy. Cancer 61: 1969–1972PubMedGoogle Scholar
  284. Kurtz JM, Jacquemier J, Torhorst J et al. (1989) Conservative therapy for breast cancer and other than infiltrating ductal carcinoma. Cancer 63: 1630–1635PubMedGoogle Scholar
  285. Lacour J, Cucalossi P, Cacers E et al. (1976) Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study. Cancer 37: 206–214Google Scholar
  286. Lannin DR, Silverman JF, Walker Ch (1986) Cost-effectiveness of fine needle biopsy of the breast. Ann Surg 203: 474 - 480PubMedGoogle Scholar
  287. Lauth G, Eulenburg R (1983) Thermographic. In: Feiereis H, Grewe He, Johannigmann J et al. (Hrsg) Brustkrebs der Frau. Marseille, München, S 83Google Scholar
  288. Lawrence BV, Lipton A, Harvey HA, Santen RJ et al. (1980) Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer 45: 786PubMedGoogle Scholar
  289. Leak GH, Berg J, Wesp EH, Robbins GF (1961) Primary treatment of patients with resectable breast cancer. Surg Gynecol Obstet 129: 953Google Scholar
  290. Lee KR, Foster RS, Papillo JL (1987) Fine needle aspiration of the breast Importance of the aspirator. Acta Cytol 31: 281–284PubMedGoogle Scholar
  291. Lee RA, Beahrs OH (1989) Surgical techniques of the modified radical mastectomy for the treatment of breast cancer. Clin Obstet Gynecol 32 /4: 830–834PubMedGoogle Scholar
  292. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR (1979) Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA 242: 49Google Scholar
  293. Leis D, Bottermann P, Ermler R, Hederkott U, Glück H (1980) The influence of high-dose of oral medroxyprogesterone acetate on glucose tolerance, serum insulin levels and adrenal response to ACTH. Arch Gynecol 230: 9PubMedGoogle Scholar
  294. Leis HP (1982) Risikofaktoren zur Entwicklung eines Mammakarzinoms. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stuttgart, S 6–11Google Scholar
  295. Leis HP jr (1988) Breast lesions. Diagnosis and treatment. In: Barber HRK (ed) Gynecology. Practice of surgery. Woodbury, ConnGoogle Scholar
  296. Lejour M (1982) Reconstruction of the breast with a contralateral epigastric rectus myocutaneous flap. Chir Plast 6: 181Google Scholar
  297. Lejour M, Eder H, De Mey A, Mattheiem W (1980) Breast reconstruction at the Tumor Centre of the University of Brussels. A three year report. Acta Chir Belg 79: 135Google Scholar
  298. Leonhardt A (1988) Beobachtungen und Probleme bei der TNM-Klassifikation von Mammakarzinomen. Geburtshilfe Frauenheilkd 48: 318–321PubMedGoogle Scholar
  299. Lerner HJ, Band PR, Israel L, Leung BS (1976) Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep 60: 1431–1435PubMedGoogle Scholar
  300. Lester G (1984) The contribution of radiology to the diagnosis, management and care of breast cancer. Radiology 151:1 Levitt SH, McHugh RB (1975) Early breast cancer and postoperative irradiation. Lancet 2: 1258–1259Google Scholar
  301. Levitt SH, McHugh RB (1977) Radiotherapy in the postoperative treatment of operable cancer in the breast Part I. Critique of the clinical and biometric aspects of the trial. Cancer 39: 924–932Google Scholar
  302. Limburg H, Krähe M (1964) Züchtung von menschlichem Krebsgewebe in der Gewebekultur und seine Sensibilitätstestung gegen neuere Zytostatika. Dtsch Med Wochenschr 89: 1938PubMedGoogle Scholar
  303. Lippman ME, Sorace RA, Bagley C et al. (1986) Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. Natl Cancer Inst Monogr 1:153– 159Google Scholar
  304. Lipton A, Harvey HA, Santen RJ, Boucher A et al. (1982) Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res [Suppl] 42: 3434Google Scholar
  305. Lipton A, Santen RJ, Harvey HA (1984) Aminoglutethimid beim metastasierenden Mammakarzinom. In: Nagel GA, Schmidt-Matthiesen H, Drees N (Hrsg) Aminoglutethimid: Ein Antiöstrogen mit Aromatasehemmung. Zuckschwerdt, München, S 20Google Scholar
  306. Löbel M, Schöndorf H, Bastert G (1987) Die Kerngröße von Mammakarzinomzellen in der Punktionszytologie als objektiver Malignitätsparameter. Arch Gynecol 242: 294–296Google Scholar
  307. Logan WPD (1975) World Health Statistics. WHO Rep 28 Ludwig Breast Cancer Study Group (1984) Randomized trial of chemo endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1: 1256–1260Google Scholar
  308. Ludwig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node- positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319: 677–683Google Scholar
  309. Lynch HT (1981) Genetics and breast cancer. Van Nostrand Reinhold, New York Maass H (1979) Die klinische Anwendung von AntiÖstrogenen. Gynäkologe 12: 212–218Google Scholar
  310. Maass H, Engel B, Trams G, Nowakowski H, Stolzenbach G (1975) Steroid hormone receptors in human breast cancer and the clinical significance. J Steroid Biochem 6: 743PubMedGoogle Scholar
  311. MacMahon B, Cole P, Brown J (1973) Etiology of human breast cancer: a review. JNCI 50; 21Google Scholar
  312. Madden JL (1965) Modified radical mastectomy. Surg Gynecol Obstet 121:1221 Maier WP, Rosemond GP, Goldman LJ et al. (1977) A ten year study of medullary carcinoma of the breast Surg Gynecol Obstet 144: 695Google Scholar
  313. Maillot K von (1983) Steroidrezeptor-Bestimmung und Hormontherapie. In: Feiereis H, Grewe HE, Johannigmann J et al. (Hrsg) Brustkrebs der Frau. Marseille, München, S 161Google Scholar
  314. Maliniac JW (1943) Arterial blood supply of the breast. Arch Surg 47: 329Google Scholar
  315. Manni A, Arafah BM (1981) Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature. Cancer 48: 873–875PubMedGoogle Scholar
  316. Manni A, Pearson OH (1980) Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treatm Rep 64: 779Google Scholar
  317. Mansour EG, Grey R, Shatila AH et al. (1989) Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 320: 485–490Google Scholar
  318. Martin HE, Ellis EB (1930) Biopsy by needle puncture and aspiration. Ann Surg 92: 169–181PubMedGoogle Scholar
  319. Mattsson W (1980) A phase DI trial of treatment with tamoxifen versus treatment with high-dose medroxy-progesterone acetate in advanced postmenopausal breast cancer. In: Jacobeiii S, Di Marco AR (eds) Role of medroxyprogesterone in endocrine-related tumors. Raven, New York, p 65Google Scholar
  320. Maugh HT, Marx JL (1979) Zerstörendes Wachstum. Entstehung und Behandlung des Krebses. Thieme, StuttgartGoogle Scholar
  321. McDivitt RW, Holler AJ, Foote FW jr (1968a) Prior breast disease in patients treated for papillary carcinoma. Arch Pathol 85: 117PubMedGoogle Scholar
  322. McDivitt RW, Stewart FS, Berg JS (1968b) Atlas of tumour pathology, tumours of the breast Armed Forces Institute of Pathology. Walter Reed Hospital, Washington D.C.Google Scholar
  323. McDivitt RW, Hutter RVP, Foote FW, Stewart FW (1969) Insitu lobular carcinoma: a prospective follow-up study indicating cumulative patient risk. JAMA 201: 82Google Scholar
  324. McDivitt RW, Stone KR, Craig RB, Palmer JO, Meyer JS, Bauer WS (1986) A proposed classification of breast cancer based on kinetic information. Cancer 57: 269–276PubMedGoogle Scholar
  325. McWhirter R (1955) Simple mastectomy and radiotherapy in the treatment of breast cancer. Br J Radiol 28: 128PubMedGoogle Scholar
  326. Meerwein F (1981) Einführung in die Psycho-Onkologie. Huber, Bern Merkel DE, McGuire WL (1990) Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer 65: 1194–1205Google Scholar
  327. Mettlin C (1984) Diet and the epidemiology of human breast cancer. Cancer 53: 605PubMedGoogle Scholar
  328. Metzger U, Weder W, Roethlin, Largiader F (1991) Phase II-study of intraarterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. Ree res in cancer res Vol 121, in pressGoogle Scholar
  329. Meyer JS, Bauer WC (1975) In-vitro determination of tritiated thymidin labeling index. Cancer 36: 1379Google Scholar
  330. Miccoli F, Iacconi P, Simi U, Roncella M, Arganini M, Melis GB (1986) Fine needle aspiration in the diagnosis of breast masses: our experience. Eur J Surg Oncol 12:123– 126Google Scholar
  331. Michel RT, Bastert G, Fortmeyer HP (1987) Steroidhormonrezeptoren unter hormoneller und zytostatischer Behandlung. Therapieergebnisse an heterotransplantierten menschlichen Mammakarzinomen. In: Schmidt CG, Schmid-Matthiesen H (Hrsg) Medroxypro- gesteronacetat (MPA) in der Onkologie. Schattauer, Stuttgart, S 187Google Scholar
  332. Miller AB (1977) Role of nutrition in the etiology of breast cancer. Cancer 39: 2704PubMedGoogle Scholar
  333. Miller EB (1966) Five-year review of carcinoma of the breast. Analysis according to Columbia classification. Ann Surg 163: 629PubMedGoogle Scholar
  334. Millis RR (1984) Needle biopsy of the breast Monogr Pathol 25: 186–203Google Scholar
  335. Minkowitz S, Moskowitz R, Khafit RA, Alderete MN (1986) Tru-cut-needle biopsy of the breast. An analysis of its specificity and sensivity. Cancer 57: 320–323Google Scholar
  336. Montague ED, Fletcher GH (1980) The curative value of irradiation in the treatment of nondisseminated breast cancer. Cancer 46: 995–998PubMedGoogle Scholar
  337. Montague ED, Spanos WJ jr, Fletcher GH (1982) Die Entwicklung der Behandlungsmethoden bei der Primärtherapie des nichtmetastasierten Mammakarzinoms. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stuttgart, S 201–207Google Scholar
  338. Montgomery TL (1961) Detection and disposal of breast cancer in pregnancy. Am J Obstet Gynecol 81: 926PubMedGoogle Scholar
  339. Mouridsen HT, Palshof T, Engelsman E, Sylvester R (1980a) CMF versus CMFplus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. In: Mouridsen HT, Palshof T (eds) Breast cancer. Experimental and clinical aspects. Pergamon, Oxford, p 119Google Scholar
  340. Mouridsen HT, Salimtschik M, Dombernowsky P et al. (1980b) Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women. In: Mouridsen HT, Palshof T (eds) Breast cancer. Experimental and clinical aspects. Pergamon, Oxford, p 107Google Scholar
  341. Müller A, Kubli F, Tschahargane C, Schindler E, Kaufmann M (1986) Bedeutung der histologischen Aufarbeitung der Axilla beim Staging des invasiven Mammakarzinoms. In: Herrnanek P (Hrsg) Bedeutung des TNM-Systems für die klinische Onkologie. Zuck- schwerdt, München, S 54–59Google Scholar
  342. Murray RML, Pitt P (1984) Die Behandlung des fortgeschrittenen Mamma-, Prostata- und Endometriumkarzinoms mit Aminoglutethimid. In: Nagel GA, Schmidt-Matthiesen H, Drees N (Hrsg) Aminoglutethimid: Ein Antiöstrogen mit Aromatasehemmung. Zuck- schwerdt, München, S 68Google Scholar
  343. Müsch E, Mackes KG, Bode U, Werner A, Merkle E, Peiss J (1988) Intrapleurale Applikation von Mitoxantron. In: Seeber S, Aigner KR, Enghofer E (Hrsg) Die lokoregionale Tumortherapie. Onkologisches Kolloquium 2. de Gruyter, Berlin, S 71–79Google Scholar
  344. Musey VC, Collins DC, Musey PI, Martion-Saltzman D, Preedy JRK (1987) Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 316: 229PubMedGoogle Scholar
  345. Namer M, Chevalier B, Guiochet N et al. (1987) Epirubicin in advanced breast cancer. Preliminary results. 4th EORTC Breast Cancer Working Conference, London (abstract F 2. 13 )Google Scholar
  346. National Cancer Institute (1980) Breast cancer: a measure of progress in public understanding. Publication No. 81–2291, PHS, DHHSGoogle Scholar
  347. National Center for Health Statistics (1984) Vital statistics in the United States, vol 2. Mortality, part B: 1982.Google Scholar
  348. National Center for Health Statistics, Rockville Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP (1980) Management and survival of female breast cancer. Cancer 45: 2917–2924Google Scholar
  349. Newman RA, Klein PJ, Uhlenbuck G, Citoler P, Karduck K (1979) The presence and significance of the Thomsen-Friedenreich antigen in breast cancer. I. Serological studies. J Cancer Res Clin Oncol 93: 181Google Scholar
  350. Nissen-Meyer R (1979) One short chemotherapy course in primary breast cancer: 12 year follow-up in series 1 of the Scandinavian Adjuvant Chemotherapy Study Group. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer I I. Grune & Stratton, New YorkGoogle Scholar
  351. Nordenström B, Azjicek J (1977) Stereotaxic needle biopsy and preoperative indication of nonpalpable mammary lesion. Acta Cytol 21: 350–351PubMedGoogle Scholar
  352. Nugent P, O’Connell TX (1985) Breast cancer and pregnancy. Arch Surg 120: 122Google Scholar
  353. Osteen RT, Connolly JL, Recht A et al. (1987) Identification of patients at high risk for local recurrence after conservative surgery and radiation therapy for state I + II. Arch Surg 122: 1248–1252PubMedGoogle Scholar
  354. Oster MW, Park Y (1983) Vincristine, adriamycin, and mitomycin ( VAM) therapy for previously treated breast cancer. Cancer 51: 203Google Scholar
  355. Otto RC (1980) Aktuelle Röntgendiagnostik im Kampf gegen den Brustkrebs. Huber, BernGoogle Scholar
  356. Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P (1978) A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetat. Cancer Treat Rep 62: 499–504PubMedGoogle Scholar
  357. Pannuti F, Martoni A, Di Marco AD, Piana E et al. (1979) Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate ( MPA) in the treatment of metastatic breast cancer. Eur J Cancer 15: 593–601PubMedGoogle Scholar
  358. Patey DH, Dyson WH (1948) The prognosis of carcinoma of the breast in relation to type of operation performed. Br J Cancer 2: 7PubMedGoogle Scholar
  359. Pavesi L, Preti P, Cuzzoni Q, Da Prada GA et al. (1983) Hochdosiertes Medroxyproge- steronacetat (HD-MAP) in Kombination mit Zytostatika in der Behandlung des fortgeschrittenen Brustkrebses. In: Lanius P, Nagel GA, Robustelli della Cuna G (Hrsg) Deutsch-italienisches onkologisches Symposium: Medroxyprogesteronacetat in der The-rapie des fortgeschrittenen Mammakarzinoms. Kehrer, Freiburg/Br, S 123Google Scholar
  360. Pearson OH (1982) Moderne Aspekte bei der endokrinen Behandlung des Mammakarzinoms. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stuttgart, S 233Google Scholar
  361. Philip J, Harris WG, Flaherty C, Joslin CA, Rustage IH, Wijesinghe DP (1984) Breast self- examination: clinical results from a population-based prospective study. Br J Cancer 50: 7–12PubMedGoogle Scholar
  362. Philip J, Harris WG, Flaherty C, Joslin CA (1986) Clinical measures to assess the practice and efficiency of breast self-examination. Cancer 58: 973–977PubMedGoogle Scholar
  363. Pierquin B, Owen RW, Maylin C, Otmezguine Y, Raynal M, Müller W, Hannoun S (1980)Radical radiation therapy of breast cancer. Int J Radiat Oncol Biol Phys 6: 17–24Google Scholar
  364. Pierquin B, LeBourgeois JP, Brun B, Mazeron JJ, Huart J (1981) Radiotherapy as primary treatment of operable breast cancer. Williams & Wilkins, Baltimore, p 175Google Scholar
  365. Pierquin B, Otmetzquine Y, Lobo PA (1985) Conservative management of breast carcinoma. In: Zander J, Balzer J (eds) Early breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 276–284Google Scholar
  366. Poortman JJ, Thijssen HH, Schwartz F (1973) Androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients. J Clin Endocrinol 37: 101Google Scholar
  367. Possinger K, Sauer HJ, Wilmanns W (1988) Chemotherapie metastasierter Mammakarzinome. Dtsch Med Wochenschr 113: 224–231PubMedGoogle Scholar
  368. Powles TJ, Coombs RC, Smith IE (1984) Erfahrungen mit Aminoglutethimid in der Behandlung von Patientinnen mit metastasierendem Mammakarzinom. In: Nagel GA, Schmidt- Matthiesen H, Drees N (Hrsg) Aminoglutethimid: Ein Antiöstrogen mit Aromatasehem- mung. Zuckschwerdt, München, S 35Google Scholar
  369. Preda F, Pizzocaro G, Oriana S, Riboldi G et al. (1979) Correlation between clinical response to bilateral oophorectomy, estrogen receptors and urinary androgen excretion in 49 patients with advanced breast cancer. Tumori 65: 325–330PubMedGoogle Scholar
  370. Preda F, Oriana S, Di Fronzo G, Secretto G et al. (1983) Long-term response to ovariectomy in 35 premenopausal patients with advanced breast cancer, treated in coherence with hormonal tests. Tumori 69: 343–347PubMedGoogle Scholar
  371. Pritchard KI, Thomson DB, Myers RE, Sutherland DJA, Mobbs BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787PubMedGoogle Scholar
  372. Prosnitz LR, Goldenberg IS, Packard RA et al. (1977) Radiation therapy as initial treatment for early stage cancer of the breast without mastectomy. Cancer 39: 917PubMedGoogle Scholar
  373. Prpic RW, Martinac P (1982) Reconstruction of the breast as a primary and secondary procedure. Breast cancer and breast reconstruction. Thieme, Stuttgart, S 175 - 177Google Scholar
  374. Quednau D, Garbrecht M, Stolzenbach G, Nowakowski H (1978) Rebound-Phänomen nach additiver endokriner Therapie des metastasierenden Mammakarzinoms der Frau mit Ae- thinylöstradiol. Dtsch Med Wochenschr 103: 2029 - 2032PubMedGoogle Scholar
  375. Radovan C (1982) Breast reconstruction after mastectomy using the temporary expander. Plast Reconstr Surg 69: 195–206PubMedGoogle Scholar
  376. Ragaz J, Manji M, Olivotto I et al. (1987) Role of mastectomy in preoperative (neoadjuvant) combined modality therapy of locally advanced breast cancer. Proc Am Soc Clin Oncol 6: 55Google Scholar
  377. Ragaz J, Goldie JH, Baird R, Rebbeck P, Basco V, Coldman A (1989) Experimental basis and clinical reality of preoperative (neoadjuvant) chemotherapy in breast cancer. In: Senn HJ, Goldhirsch A, Gelber RD, Osterwalder B (eds) Adjuvant therapy of primary breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 28–35Google Scholar
  378. Roberts JG, Preece PE, Bolton PM, Baum M, Hughes LE (1975) The “tru-cut”-biopsy in breast cancer. Clin Oncol 1: 297–303PubMedGoogle Scholar
  379. Roberts MM, Alexander FE, Anderson TJ (1984) The Edinbourgh randomized trial of screening for breast cancer. Br J Cancer 50: 77Google Scholar
  380. Robustelli della Cuna G, Pellegrini A (1984) Medroxyprogesterone acetate in combination with chemotherapy for advanced breast cancer: updated results and criticisms. In: Pellegrini A, Robustelli della Cuna G, Pannuti F, Pouillart P, Jonat W (eds) Role of medroxyprogesterone in endocrine-related tumors, vol 3. Raven, New York, p 91Google Scholar
  381. Robustelli Della Cuna G, Calciati A, Bernardo-Strada MR, Bumma C, Campio L (1978) High-dose MPA treatment in metastatic carcinoma of the breast. A dose response evaluation. Tumori 64: 143–149Google Scholar
  382. Rodes ND, Lopez MJ, Pearson DK et al. (1986) The impact of breast cancer screening on survival: a 5 to 10 year follow-up study. Cancer 57: 581PubMedGoogle Scholar
  383. Romsdahl MM, Sears ME, Eckles NE (1970) Posttreatment evaluation of breast cancer. In: Anderson MD (ed) Hospital breast cancer: early and late. Yearbook Med, Chicago, p 291Google Scholar
  384. Ronai G (1990) Prophylaktische, onkologische Aspekte für die Behandlung der kontralateralen Brust. 1. Jahrestagung der AWO. Int Symp über neue Entwicklungen zur Erhaltung und Wiederherstellung der Brust beim Mammakarzinom. Berlin 23.–25. 2. 90Google Scholar
  385. Ronai G, Tulusan AH, Schmidt C, Mennel C (1989) Multizentrizität invasiver und mikroinvasiver Mammakarzinome. Arch Gynecol Obstet 245: 726–727Google Scholar
  386. Rosemond GP (1964) Management of patients with carcinoma of the breast in pregnancy. Ann NY Acad Sei 114: 851Google Scholar
  387. Rosen PP (1980) Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancer 46: 1298–1306PubMedGoogle Scholar
  388. Rosenberg AL, Schwartz JF, Feig SA (1987) Clinically occult breast lesions: localization and significance. Radiology 162: 167PubMedGoogle Scholar
  389. Rosner D, Nemoto T, Lane WW (1988) Sequential hormonal-chemotherapy improves survival in metastatic breast cancer in estrogen receptor positive and unknown patients. Proc Am Soc Clin Oncol 7: 66Google Scholar
  390. Ross MB, Buzdar AU, Blumenschein GR (1982) Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 49: 413–417PubMedGoogle Scholar
  391. Rotter H (1896) Günstigere Dauererfolge durch ein verbessertes Operationsverfahren der Mammakarzinome. Klin Wochenschr 1: 99Google Scholar
  392. Rouviere H (1932) Anatomie des lymphatiques de Thomme. Masson, ParisGoogle Scholar
  393. Rüegg P, Sulser H (1975) Cystosarcoma phylloides mammae. Analyse von 58 Fällen. Schweiz Med Wochenschr 105: 1346PubMedGoogle Scholar
  394. Salmon SE (1980) Cloning of human tumor stem cells. Liss, New YorkGoogle Scholar
  395. Saltzstein SL (1984) Limits of physical examination and breast self-examination in detecting cancers of the breast An unselected population-based study of 1302 cases. Cancer 54: 1443–1446PubMedGoogle Scholar
  396. Santen RJ, Samojlik E, Lipton A, Harvey H, Ruby EB, Wells SA, Kendall J (1977) Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 39:2948- 2958Google Scholar
  397. Santen RJ, Santner S, Davis B, Veldhuis J et al. (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast cancer. J Clin Endocrinol 47: 1257Google Scholar
  398. Santen RJ, Samojlik E, Worgul TJ (1981a) Aminoglutethimide. In: Santen RJ, Henderson IC (eds) Aminoglutethimid. Karger, Basel, pp 101–160Google Scholar
  399. Santen RJ, Wiorgul TJ, Samojlik E, Interrante A et al. (1981b) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545–551PubMedGoogle Scholar
  400. Santen RJ, Lipton A, Harvey H, Boucher AE, Henderson C (1983) Pharmacologic mechanisms of estrogen suppression with aminoglutethimide in women with breast cancer. Proc 13th Int Congress Chemotherapy 218: 21–26Google Scholar
  401. Sarrazin D, Heery M, LG M (1973) Role of routine postoperative irradiation in management of operable primary mammary cancer with lymph nodes invasion. Bull Cancer (Paris) 60: 31–40Google Scholar
  402. Sarrazin D, Le M, Lacour J, Tubiana M (1982) Die postoperative Strahlentherapie beim Mammakarzinom. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stattgart, S 196–207Google Scholar
  403. Sarrazin D, Le MG, Fontaine MF et al. (1983) Conservative treatment versus mastectomy in T1 or small T2 breast cancer: a randomized trial. In: Harris JR, Hellman S, Silen W (eds) Conservative management of breast cancer. Lippincott, Philadelphia, pp 101–114Google Scholar
  404. Sarrazin D, Le M, Rouesse J, Contessa G, Petit JY, Lacour J, Viquier J, Hill C (1984) Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less. Cancer 53: 1209–1213PubMedGoogle Scholar
  405. Schabel FM (1975) Concepts for systemic treatment of micrometastases. Lancet 33:15– 24Google Scholar
  406. Scharl A, Vierbuchen M, Conradt B, Würz H (1989) Immunhistochemische und biochemische Steroidrezeptoranalyse in Mammakarzinomen. Arch Gynecol Obstet 245/1–4:699– 700Google Scholar
  407. Schauer A (1981) Mammacarcinom. Pathol A 3: 6–39Google Scholar
  408. Schauer A (1985) Pathologie. In: Schildberg FW, Kiffner E (Hrsg) Interdisziplinäre Therapie des Mammakarzinoms. Meducation Foundation, Clyancourt Corporation AG, Cham, S 28–84Google Scholar
  409. Schauer A, Droese M, Rahlf G (1977) Pathologische Anatomie des Mammacarcinoms. Arch Klin Chir 345: 39–44Google Scholar
  410. Scheele M, Hoffmann L, Müllerleile U (1989) CEA und CA 15–3 als Parameter für Thera-pieentscheidungen beim metastasierten Mammakarzinom. Arch Gynecol Obstet 245/1– 4: 678–679Google Scholar
  411. Schenck U (1989) Leistungsfähigkeit der Feinnadelaspirationszytology. In: Benz J (Hrsg) Mamma-Karzinom. Aktueller Stand der Diagnostik. Mamma-Symposium Winterthur 1988. Babler, Bern, S 62–67Google Scholar
  412. Schenck U, Soost HJ (1983) Zytodiagnostik der Mamma. In: Feiereis H, Grewe HE, Johannigmann J et al. (Hrsg) Brustkrebs der Frau. Marseille, München, S 125Google Scholar
  413. Schenck U, Burger G, Jütting U, Eiermann W (1986) Zytomorphologisches Grading und Hormonrezeptorstatus beim Mammakarzinom. Dtsch Med Wochenschr 51 /52: 1949–1953Google Scholar
  414. Schmid L, Schröck R, Langhammer C et al. (1987) CA 15-3 and CEA in the follow-up of patients with metastatic breast cancer undergoing endocrine or cytotoxic therapy. In: Klapdor R (ed) New tumormarkers and their monoclonal antibodies. Thieme, Stuttgart, pp 80 - 86Google Scholar
  415. Schmidt-Matthiesen H, Bastert G (1987) Gynäkologische Onkologie. Schattauer, Stuttgart, S 159–160Google Scholar
  416. Schmitt EL, Threatt B (1985a) Characteristics of breast cancer in an incident cancer population. AJR 143: 403Google Scholar
  417. Schmitt EL, Threatt BA (1985b) Effective breast cancer detection with film-screen mammography. J Can Assoc Radiol 36: 304 - 307PubMedGoogle Scholar
  418. Schnitt SJ, Connolly JL, Khettry U et al. (1987) Pathologic findings on reexcision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer 56: 675Google Scholar
  419. Schöndorf H (1977) Die Aspirationszytologie der Brustdrüse. Schattauer, StuttgartGoogle Scholar
  420. Schottenfeld D, Nash AG, Robbins GF, Beattie EJ (1976) Ten-year results of the treatment of primary operable breast carcinoma. Cancer 38: 1001–1007PubMedGoogle Scholar
  421. Schreiner WE (1985) Epidemiologie, Risikofaktoren und Diagnostik des Brustkrebses. Möglichkeiten der Früherfassung. Schweiz Rundsch Med 74: 1325–1336Google Scholar
  422. Schünemann H, Beaufort F (1986) Gynäkologische Malignome. Systemische Therapie metastasierter Mamma- und Genitalmalignome, 2. Aufl. Zuckschwerdt, MünchenGoogle Scholar
  423. Schwaiger N, Herfarth C (1979) Erkrankungen der Brustdrüse. In: Schwalm H, Döderlein G (Hrsg) Klinik der Frauenheilkunde und Geburtshilfe, Bd VII. Urban & Schwarzenberg, München, S 559Google Scholar
  424. Schwegler N (1987) Die Strahlentherapie des Brustkrebses. In: Symposium Mammakarzinom. Aarau 1987. Medichemie, Basel, S 76–111Google Scholar
  425. Schweppe KW, Beller FK (1983) Schwangerschaft und maligne gynäkologische Tumoren. In: Beller FK, Kyank H (Hrsg) Erkrankungen während der Schwangerschaft. Thieme, Stuttgart u. VEB Thieme, Leipzig, S 558–576Google Scholar
  426. Seidman H, Gelb SK, Silverberg E, LaVerda N, Lubera JA (1987) Survival experience in the breast cancer detection demonstration project. Cancer 37: 258Google Scholar
  427. Senn HJ, Barett-Mahler R (Osaka and Sakk Groups) (1987) Update of Swiss adjuvant studies with LMF (VS,CMF) in operable breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, New YorkGoogle Scholar
  428. Shabot M, Goldberg JM, Schick P, Nieberg R, Pilch YH (1982) Aspiration cytology is superior to tru-cut needle biopsy in establishing the diagnosis of clinically suspicious breast masses. Am Surg 2: 122–126Google Scholar
  429. Shapiro S, Strax P, Venet L, Fink R (1968) The search for risk factors in breast cancer. Am J Public Health 58: 820Google Scholar
  430. Shipp SK, Muss HB, Westrick MA et al. (1983) Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil ( CMF ). Cancer Chemother Pharmacol 11: 30Google Scholar
  431. Shousha S (1989) Histopathology of breast carcinoma and related conditions. In: Hoogstraten B, Burn I, Bloom HJG (eds) Breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 13–44Google Scholar
  432. Sickles EA (1986) Mammographie features of 300 consecutive nonpalpable breast cancers. AJR 146: 661Google Scholar
  433. Silverberg E, Lubera J (1988) Cancer statistics 1988. Cancer J Clin 38: 2Google Scholar
  434. Silverman JF, Lannin DR, O’Brian K, Norris HT (1987) The triage role of fine needle aspiration biopsy of palpable breast masses. Diagnostic accuracy and cost-effectiveness. Acta Cytol 31: 731–736Google Scholar
  435. Silvestrini R, Daidone MG, EH Fronzo G (1979) Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44: 665–667Google Scholar
  436. Smallwood J, Herbert A, Guyer P, Taylor I (1985) Accuracy of aspiration cytology in the diagnosis of breast disease. Br J Surg 72: 841–843PubMedGoogle Scholar
  437. Smart CR, Myers MH, Gloeckler LA (1978) Implications from data on breast cancer management Cancer 41: 787–789Google Scholar
  438. Smeets HJ, Saltzstein SL, Meurer WT, Pilch YH (1986) Needle biopsies in breast cancer diagnosis: techniques in search of an audience. J Surg Oncol 32: 11–15PubMedGoogle Scholar
  439. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parson CA, Villardo A, Walsh G, McKinna JA (1981) Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised crossover trial. Br Med J 283: 1432–1434Google Scholar
  440. Soost HJ, Baur S (1980) Organisation und Arbeitsweise eines zytologischen Laboratoriums. In: Smolka H, Soost HJ (Hrsg) Gynäkologische Zytodiagnostik. Thieme, Stuttgart, S 294–295Google Scholar
  441. Speckin G, Pahnke VG, Simon WE, Trams G (1989) Biochemischer und immuncytochemi- scher Oestrogenrezeptornachweis beim Mammakarzinom. Arch Gynecol Obstet 245/1- 4: 701–702Google Scholar
  442. Spitalier JM, Gambarelli J, Brandone H et al. (1986) Breast-conserving surgery with radiation therapy for operable mammary carcinoma: a 25-year experience. World J Surg 10:1014– 1020Google Scholar
  443. Staab HJ (1985) CEA in der Diagnostik und Verlaufskontrolle von Tumorerkrankungen. In: Klietmann W (Hrsg) Aktuelle Tumormarker. Schattauer, Stuttgart, S 21 Statistisches Bundesamt Wiesbaden (1986) Gesundheitswesen. Reihe 4: Todesursachen 1985. Kohlhammer, StuttgartGoogle Scholar
  444. Statistisches Quellen werk der Schweiz (1977) Bevölkerungsbewegungen in der Schweiz, Heft 603. Eidg Statistisches Amt, BernGoogle Scholar
  445. Stauch G, Georgii A (1985) Uber den Einfluß von Probeexzisionen wegen Karzinomen der Brustdrüse auf die Lebenserwartung. In: Herfarth C, Betzler M (Hrsg) Das Mammakarzinom - eine interdisziplinäre Situationsanalyse. Karger, Basel, S 44Google Scholar
  446. Stegner HE (1987) Pathologie maligner Erkrankungen der Mamma. In: Strömbeck JO, Rosato FE (Hrsg) Mammachirurgie. Diagnostik und Behandlung von Erkrankungen der Mamma. Thieme, Stuttgart, S 73–108Google Scholar
  447. Stegner HE, Maass H, Pape C, Trams UG (1979) Estrogen receptors and ultrastnictural pathology of breast. Cancer Treat Rep 63: 1212Google Scholar
  448. Stehlin JS, de Ipolyi PD, Greff PJ, Gutierrez AE, Hardy RJ, Dahiya SL (1987) A ten year study of partial mastectomy for carcinoma of the breast. Surg Gynecol Obstet 165: 191Google Scholar
  449. Stein RC, Dougherty L, Gazet JC, Ford HT, Coombes RC (1989) Comparison of methotrexate and mitoxantrone with and without mitomycin C in the treatment of advanced breast cancer. 5th Eur Conference on Clinical Oncology (ECCO), London, Sept 3–7, 1989Google Scholar
  450. Stein W HI, Hortobagyi GN, Blumenschein GR (1983) Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol 22: 45–46PubMedGoogle Scholar
  451. Steinbeck R, Askensten U, Auer G (1989) Die Wertigkeit der DNA–Analyse in soliden Tumoren. Eine Übersicht für den klinisch tätigen Pathologen. Pathologe 10: 171–176Google Scholar
  452. Stewart HJ, Forrest AP, Gunn JM, Hamilton T, Langlands AO, McFadyen U, Roberts MM (1980) The tamoxifen trial - a double blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. In: Mouridsen HT, Palshof T (eds) Breast cancer - experimental and clinical aspects. Pergamon, Oxford, pp 83–88Google Scholar
  453. Stjernswärd J (1974) Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet 2:1285–1286 Strax P (1976) Results of mass screening for breast cancer in 50,000 examinations. Cancer 37: 30Google Scholar
  454. Strax P (1982) Die Zielsetzung bei der Durchführung von Reihenuntersuchungen zur Früherkennung des Mammakarzinoms. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, Stuttgart, S 63Google Scholar
  455. Streit A et al. (1987) Welche Untersuchungen sind zur Diagnose von Rezidiven beim operablen Mammakarzinom geeignet? Schweiz Med Wochenschr 117: 1615–1619PubMedGoogle Scholar
  456. Strender LE, Wallgren A, Arndt J et al. (1981) Adjuvant radiotherapy in operable breast cancer: correlation between dose in internal mammary nodes and prognosis. Int J Radiat Oncol Biol Phys 7: 1319–1325PubMedGoogle Scholar
  457. Stucki D, Brun del Ré R, Dickreuter W, Almendral AC, Zehnder A, Stauffer HJ (1984) Isometrische Markierung nicht palp abler mammographisch erkannter Läsionen. In: Kubli F, Founder D von (Hrsg) Neue Konzepte der Diagnostik und Therapie des Mammakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 35–36Google Scholar
  458. Svan G (1983) Stereotaxic needle biopsy of nonpalpable breast lesion: a clinical and radio-logical follow-up. Acta Radiol [Diagn] (Stockh) 24: 385–390Google Scholar
  459. Svan G, Silfversward C (1983) Stereotaxic needle biopsy of nonpalpable breast lesions: cytologic and histopathologic findings. Acta Radiol [Diagn] (Stockh) 24: 283–288Google Scholar
  460. Swain SM, Lippman ME (1989) Treatment of patients with inflammatory breast cancer. In: De Vi ta VT, Hellman S, Rosenberg SA (eds) Important advanced in oncology, 129–150Google Scholar
  461. Tabar L, Fagerberg CJ, Gad A et al. (1985) Reduction in mortality from breast cancer after mass screening with mammography. Randomized trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1:829 Tancini G, Bonadonna G, Valagussa P et al. (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2–10Google Scholar
  462. Tanneberger S, Bacigalupo G (1967) Die Benutzung von Zellkulturen zur Ermittlung der Sensibilität menschlicher Tumoren gegenüber Zytostatika. Dtsch Gesundheitswesen 22: 11Google Scholar
  463. Tapley ND, Spanos WJ, Fletcher GH, Montague EA, Schell S, Oswald MJ (1982) Results in patients with breast cancer treated by radical mastectomy and postoperative irradiation with no adjuvant chemotherapy. Cancer 49: 1316–1319PubMedGoogle Scholar
  464. Taylor IV, Olsen JE, Cummings FJ, Knuiman M (1985) Observation compared to adjuvant chemo-hormonotherapy in postmenopausal breast cancer: the ECOG trial. Proc Am Soc Clin Oncol 4: 61 (Abstract C-235)Google Scholar
  465. Taylor SE, Lichtmann RR, Wood JV, Bluming AZ, Dosik GM, Leibowitz RL (1984) Breast self-examination among diagnosed breast cancer patients. Cancer 54: 2528–2532PubMedGoogle Scholar
  466. Thomas BA, Price JL, Boulter PS, Gibbs NM (1984) The first three years of the Guildford Breast Screening Project. Recent Results Cancer Res 90: 195PubMedGoogle Scholar
  467. Thomsen K, Stegner HE, Frischbier HJ (1980) Grundlagen und Grenzen der brusterhaltenden Therapie kleiner Mammakarzinome. Gynäkologe 13: 56PubMedGoogle Scholar
  468. Thum P, Büchler E (1982) Weichteile. In: Thum P, Büchler E (Hrsg) Einführung in die Röntgendiagnostik. Thieme, Stuttgart, S 511–518Google Scholar
  469. Tomin R, Donegan WL (1987) Screening for recurrent breast-cancer - its effectiveness and prognostic value. J Clin Oncol 5: 62–67PubMedGoogle Scholar
  470. Töndury G (1970) Angewandte und topographische Anatomie. Fretz & Wasmuth, Zürich Toonkel LM, Fix I, Jacobson LH, Wallach LB (1983) The significance of local-recurrence of carcinoma of the breast. Int J Radiat Oncol Biol Phys 9: 33–39Google Scholar
  471. Tormey DC, Lippman ME, Edwards BK (1983) Evaluation to tamoxifen doses with and without fiuoxymesterone in advanced breast cancer. Ann Intern Med 98: 139–144PubMedGoogle Scholar
  472. Tormey EXÜ, Rasmussen P, Jordan VC (1987) Long–term adjuvant tamoxifen study: clinical update. Breast Cancer Res Treat 9: 157–158PubMedGoogle Scholar
  473. Treurmiet-Donker AD, Helle PA, van Putten WLJ (1986) Adjuvant postoperative radiotherapy in operable node positive mammary cancer: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 12: 2067–2072Google Scholar
  474. Tubiana M, Pejcevic J, Renaud A, Contesso G, Chavaudra N, Gioanni J, Malaise EP (1981) Kinetic parameters and the course of the disease in breast cancer. Cancer 47: 937–947PubMedGoogle Scholar
  475. Tulusan AH (1990) Mamma-Ca -Welche Frauen dürfen die Brust behalten? Medical Tribune Nr 11, März 90Google Scholar
  476. Turnball AR, Chant ADB, Buchanan RB, Turner DTL, Shepard JM, Fräser JD (1978) Treatment of early cancer. Lancet 11: 7Google Scholar
  477. Uhlenbuck G (1986) Tumormarker: Biochemische Aspekte und neue Perspektiven. Med Klin 81: 174Google Scholar
  478. UICC (1987) TNM Klassifikation maligner Tumoren, 4. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  479. Umbach GR et al. (1988) Erfahrungen in der Nachsorge von Patientinnen mit Mammakarzinom. Geburtshilfe Frauenheilkd 48: 292–298PubMedGoogle Scholar
  480. Ungeheuer E, Lüders K (1978) Chirurgische Behandlung des Mammakarzinoms. Dtsch Ärztebl 4: 161Google Scholar
  481. Unteh M, Harbeck N, Eiermann W (1989) Tumorzellen im Knochenmark bei Brustkrebspatientinnen zum Zeitpunkt der Primärtherapie: Nachbeobachtungen über 3 Jahre. Arch Gynecol Obstet 245: 724–726Google Scholar
  482. Urban JA (1973) Reconstruction after mastectomy. In: Synderman RK (ed) Symposium on neoplastic and reconstructive problems of the female breast. Mosby, St Louis, pp 65–73Google Scholar
  483. Urban JA, Marjani MA (1971) Significance of internal mammary lymph node metastases in breast cancer. AJR 111: 130–136Google Scholar
  484. Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Cancer 41: 1170PubMedGoogle Scholar
  485. Valagussa P, Tess T, Rossi A, Tancini G, Bonadonna G (1980) Has adjuvant CMF altered the patterns of first recurrence in operable breast cancer with N+? Proc ASCO Abstract C–375Google Scholar
  486. Valagussa P, Brambilla C, Bonadonna G (1989) Chemotherapy of advanced disease. In: Hoogstraten B, Burn I, Bloom HJG (eds) Breast cancer. UICC. Springer, Berlin Heidelberg New York Tokyo, pp 233–256Google Scholar
  487. Van der Linde F (1989) Neue Gesichtspunkte zur Epidemiologie. In: Benz J (Hrsg) Mamma-Karzinom. Aktueller Stand der Diagnostik. Mamma-Symposium Winterthur 1988. Bäbler, Bern, S 21–29Google Scholar
  488. Verhaege M, Cornillot M, Herbeau J, Wurtz A (1969) Le triple diagnostic cyto-radio-clinique dans les tumours du sein. Mem Acad Chir 123: 48–61Google Scholar
  489. Vermund L (1964) Trends in radiotherapy of breast cancer. In: Proc of the Fifth National Cancer Conference. Lippincott, Philadelphia, pp 183–204Google Scholar
  490. Veronesi U (1977) New trends in the treatment of breast cancer at the cancer institute of Milan. AJR 128: 287–289PubMedGoogle Scholar
  491. Veronesi U (1987) Rationale and indications for limited surgery in breast cancer: current data. World J Surg 11: 493PubMedGoogle Scholar
  492. Veronesi U (1989) Breast cancer: new trends in surgery and radiotherapy. Eur J Gynecol Oncol 3: 196–198Google Scholar
  493. Veronesi U, Saccozzi R, Del Vecchio M et al. (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305: 6–11PubMedGoogle Scholar
  494. Veronesi U, Banfi A, Delveccia M, Saccazzi R et al. (1986a) Comparison of Halsted mastectomy with quadrantectomy, axillary dissection and radiotherapy in early breast cancer. Long-term results. Eur J Cancer Clin Oncol 22: 1085–1089Google Scholar
  495. Veronesi U, Zucali R, Luini A (1986b) Local control and survival in early breast cancer: The Milan trial. Int J Radiat Oncol Biol Phys 12: 717–720Google Scholar
  496. Vessey MP, Doll R, Jones K, McPherson K, Yeates D (1979) An epidemiological study of oral contraceptives and breast cancer. Br Med J 1: 1755Google Scholar
  497. Vessey MP, McPherson K, Doll R (1981) Breast cancer and oral contraceptives findings in Oxford- Family Planning Association contraceptives study. Br Med J 282: 2093Google Scholar
  498. Virchow R (1858) Cellularpathologie in ihrer Begründung auf die physiologische und pathologische Gewebelehre. Hirschwald, BerlinGoogle Scholar
  499. Volm M, Kaufmann M, Wayss K, Goerttler K, Mattern J (1974) Gezielte Tumor-Chemotherapie durch Onkobiogramme. Dtsch Med Wochenschr 99: 38PubMedGoogle Scholar
  500. Vorherr H (1980) Breast cancer. Urban & Schwarzenberg, MünchenGoogle Scholar
  501. Vorherr H (1981) Pathobiology of breast cancer: hypothesis of biological predetermination and long-term survival. Klin Wochenschr 59: 819PubMedGoogle Scholar
  502. Vorherr H, Müller E (1981) Epidemiologie und Pathogenese des Mammakarzinoms. Ther Gegenwart 120: 806PubMedGoogle Scholar
  503. Wada T, Koyama H, Terasawa T (1981) Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65: 728PubMedGoogle Scholar
  504. Wagner H (1985) Topographische Anatomie der weiblichen Brust. In: Beller FK (Hrsg) Atlas der Mammachirurgie. Schattauer, Stuttgart New York, S 2–26Google Scholar
  505. Wallgren A, Amer O, Bergström J et al. (1980) The value of preoperative radiotherapy in operable mammary carcinoma. Int J Radiat Oncol Biol Phys 6: 287–290PubMedGoogle Scholar
  506. Wallgren A, Arner O, Bergström J et al. (1986) Radiation therapy in operable breast cancer:–results from the Stockholm trial on adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 12: 533–537PubMedGoogle Scholar
  507. Waither E, Hünig R, Almendral AC et al. (1988) Brusterhaltende Therapie: diagnostische Probleme in der Nachsorge. Helv Chir Acta 55: 909–915Google Scholar
  508. Wander HE, Nagel GA (1983) Adjuvante Chemotherapie beim Mammakarzinom. Dtsch Ärztebl 42: 47–53Google Scholar
  509. Wander HE, Kleeberg UR, Schachner-Wünschmann E, Nagel GA (1987) A long-acting depot preparation of a synthetic GnRH agonist (Zoladex) in the treatment of pre- and postmenopausal advanced breast cancer (BC). 3rd Int congress on hormones and cancer, HamburgGoogle Scholar
  510. Wandt H, Bruntsch U, Gallmeier WM (1990) Sinnvolle Nachsorge des Mammakarzinoms. Gynäkol Prax 14: 1–9Google Scholar
  511. Walterhouse J, Muir CS, Shanmugaratnom K, Powell JG (eds) (1982) Cancer incidence in five continents. IARC 4Google Scholar
  512. Watson DP, McGuire M, Nicholson F, Given HF (1987) Aspiration cytology and its relevance to the diagnosis of solid tumors of the breast. Surg Gynecol Obstet 165: 435–441PubMedGoogle Scholar
  513. Weichselbaum RR, Marek A, Hellmann S (1976) The role of postoperative irridiation in carcinoma of the breast. Cancer 37: 2882Google Scholar
  514. Weikel W, Beck T, Rosenthal H, Grill HJ (1989) Immunhistochemische Progesteronrezeptorbestimmung (mPRI) beim Mammacarcinom. Arch Gynecol Obstet 245/1–4: 700–701Google Scholar
  515. Weissgerber U, Herzog RE, Seufert R (1987) Das DNS–Histogramm als Prognosefaktor des Mammakarzinoms. In: Beller FK, Seitzer D (Hrsg) 7. Wissenschaftliche Tagung der Deutschen Gesellschaft für Senologie 25.–27. September 1987. HUF, Mülheim (Ruhr), S 197–198Google Scholar
  516. Wertheim U, Ozello L (1980) Neoplastic involvement of nipple and skin flap in carcinoma of the breast. Am J Surg Pathol 4: 543PubMedGoogle Scholar
  517. Westbrook KG, Gallager HS (1975) Intraductal carcinoma in the breast. A comparative study. Am J Surg 130: 667Google Scholar
  518. White TT (1955) Prognosis of breast cancer for pregnant and nursing women. Analysis of 1413 cases. Surg Gynecol Obstet 100: 661PubMedGoogle Scholar
  519. WHO (1982) Histologische Klassifikation von Mammakarzinomen. In: Schmidt-Matthiesen H (Hrsg) Spezielle gynäkologische Onkologie IL Malignome der Mamma (Baster G). Urban & Schwarzenberg, München, S 144Google Scholar
  520. Willgeroth F, Rummel W, Säbel M, Kuhn H, Ascherl E (1978) Intraoperativer Nachweis von Mikroverkalkungen der Brust mit einem Durchleuchtungsgerät. Geburtshilfe Frauenheilkd 38: 636–639PubMedGoogle Scholar
  521. Williams MR, Walerk KJ, Turkes A, Blarney RW, Nicholson RJ (1986) The use of an LH–RH–agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629–636Google Scholar
  522. Wilson RE, Donegan WL, Mettlin C, Smart CR, Murphy GP (1984) The 1982 National Survey of Carcinoma of the Breast in the United States by the American College of Surgeons. Surg Gynecol Obstet 159: 309–318PubMedGoogle Scholar
  523. Winchester DP et al. (1979) Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 43: 956–960PubMedGoogle Scholar
  524. Winkel K zum (1982) Primäre Strahlentherapie des Mammakarzinoms. In: Frommhold W, Gerhardt P (Hrsg) Das Mammakarzinom. Thieme, Stuttgart, S 128–138Google Scholar
  525. Witt H, Bürger H, Flesch U, Stein F (1981) Mammadiagnostik im Röntgenbild. Ein Atlas für die Praxis mit histologischen Schnitten, de Gruyter, BerlinGoogle Scholar
  526. Wolfe JN, Albert S, Belle S, Salane M (1982) Breast parenchymal patterns: analysis of 332 incident breast carcinomas. AJR 138: 113–118PubMedGoogle Scholar
  527. Wolfe JN, Buck K, Salane M et al. (1987) Xeroradiography of the breast: overview of 21,057 consecutive cases. Radiology 165: 305PubMedGoogle Scholar
  528. Wöllgens P, Voss AC, Barth V, Klöckner D (1973) Das lokale Frührezidiv beim Mammakarzinom. Eine vergleichende Studie von 5 verschiedenen Behandlungstechniken bei 368 Patienten. Strahlentherapie 146: 1–6PubMedGoogle Scholar
  529. Wynder EL (1980) Dietary factors related to breast cancer. Cancer 46: 899PubMedGoogle Scholar
  530. Young GP, Somers RG, Young I, Kaplan M, Cowan DF (1986) Experience with a modified fine–needle aspiration biopsy technique in 533 breast cases. Diagn Cytopathol 212: 91–98Google Scholar
  531. Zajicek J (1974) Aspiration biopsy cytology of supradiaphragmatic organs. In: Wied GL (ed) Clinical oncology 4. Karger, Basel, pp 185–190Google Scholar
  532. Zajicek J (1978) Aspiration biopsy cytology of breast carcinoma. In: Grundmann E, Beck L (eds) Early diagnosis of breast cancer, methods and results. Fischer, Stuttgart (Cancer Campaign vol 1, pp 175–181 )Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Ossi R. Köchli
    • 1
  • Bernd-Uwe Sevin
    • 2
  • Jörg Benz
    • 3
  • Edgar Petru
    • 2
  • Urs Haller
    • 4
  1. 1.Frauenklinik FrauenfeldThurgauisches KantonsspitalFrauenfeldSwitzerland
  2. 2.Department of Obstetrics and Gynecology Division of Gynecologic OncologyUniversity of Miami School of MedicineMiamiUSA
  3. 3.Frauenklinik WinterthurKantonsspital WinterthurWinterthurSwitzerland
  4. 4.Universitätspital ZürichZürichSwitzerland

Personalised recommendations